Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Prostatic Neoplasms: HELP
Johann Sebastian de Bono
Based on 226 articles published since 2008
||||
Expertise Level
The expertise of Johann Sebastian de Bono ranks in the
  • Top 0.0024%
  • ... of 127,126 published authors worldwide on Prostatic Neoplasms
  • ... from 2008 through 2018
  • ... based on contributions to 226 articles on the topic.
Graphical view (beta)
Uncounted papers?
Get your prestigious
World Expert badge
similar to this:
 
Aliases de Bono, Johann Sebastian   ·   De Bono, Johann S   ·   De-Bono, Johann S   ·   de Bono, J S   ·   De Bono, Johann   ·   De-Bono, J   ·   De Bono, J S   ·   de Bono, J   ·   de Bono, Johann S   ·   De-Bono, Johann   ·   de Bono, Johann
Work Locations
Details
Most likely:    University of London      
2018
  • Menarini Silicon Biosystems spa, Bologna, Italy. · Department of General, Visceral and Pediatric Surgery, Medical Faculty, University Hospital of the Heinrich- Heine-University Düsseldorf, Düsseldorf, Germany. · Unità Operativa di Oncologia Medica, Policlinico Sant'Orsola - Malpighi, Bologna, Italy. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Pubmed 29494651
  • Tulane University School of Medicine, New Orleans, LA · Institute of Cancer Research, London, United Kingdom · Pubmed 29694820
2017
  • Eastern Health & Monash University, Melbourne, Australia. · Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland and University of Bern, Switzerland. · Europa Uomo Prostate Patients, Clayhall Ilford, UK. · The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, UK. · Knight Cancer Institute, Oregon Health & Science University, Portland, USA. · BC Cancer Agency and University of British Columbia, Vancouver, Canada. · Department of Medical Oncology, Guy's Hospital, London, UK. · Monash University Eastern Health Clinical School, Melbourne, Australia. · Division of Haematology/Oncology, Columbia University Medical Center, New York. · Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. · Department of Cancer Medicine, Institut Paoli Calmette, Marseille, France. · Fred Hutchinson Cancer Research Center, University of Washington, Seattle. · Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA. · Clinical Oncology Unit, Queen Elizabeth Hospital Birmingham, University of Birmingham, Birmingham, UK. · Department of Clinical Therapeutics, David H. Koch Centre, Alexandra Hospital, University of Athens, Athens, Greece. · Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, USA. · Clinical Oncology Academic Unit, Royal Marsden NHS Foundation Trust, London, UK. · Clinical Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), San Francisco, USA. · Department of Surgery, Centre Hospitalier de Université de Montréal, Montreal, Canada. · Department of Medicine and Urology, Tulane Cancer Center, New Orleans. · Department of Medicine, University of California, San Francisco, USA. · Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. · Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, USA. · Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada. · Cliniques Universitaires Saint Luc, Brussels, Belgium. · Pubmed 28838209
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28419178
  • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 28233594
  • Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28000989
  • The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. · Pubmed 27753448
  • Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Department of Urology, Weill Cornell Medicine, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. · Sheffield Institute for Nucleic Acids, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain; Medical Oncology Department, CNIO-IBIMA Genitourinary Cancer Unit, Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. · Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 27590317
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. · Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, United Kingdom. · Academic Urology Unit, Royal Marsden Hospital, Sutton, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. Electronic address: · Pubmed 28606735
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · The University of Michigan, Ann Arbor, Michigan. · Peter MacCallum Cancer Centre, Melbourne, Australia. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28450425
  • OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Electronic address: · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Cancer Medicine, Gustave Roussy, University of Paris-Sud, Villejuif, France. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium. · Department of Medical Oncology, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. · Department of Medicine, University of Colorado School of Medicine, Aurora, CO. · Department of Medical Oncology, USC Norris Cancer Hospital, Keck Medical Center of USC, Los Angeles, CA. · Department of Biostatistics, Astellas Pharma Europe, BV, Leiden, Netherlands. · Department of Biostatistics, Medivation, Inc, San Francisco, CA. · Department of Clinical Development, Medivation, Inc, San Francisco, CA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. · Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA. · Pubmed 28344102
  • Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. Electronic address: · Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Trial Architecture Consulting, Washington, DC, USA. · Centre Antoine Lacassagne, Nice, France. · Florida Cancer Specialists, Fort Myers, FL, USA. · Department of Urology, Tübingen, Germany. · Institut Paoli Calmette, Department of Cancer Medicine, Marseille, France. · Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany. · University of Tübingen, Tübingen, Germany. · Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada. · Durham Regional Cancer Centre, Oshawa, ON, Canada. · Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. · OncoGenex Pharmaceuticals, Bothell, WA, USA. · Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Pubmed 28283282
  • Drug Development Department, Gustave Roussy, University of Paris Sud, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · BC Cancer Agency, Vancouver, Canada. · University Hospital 12 de Octubre, CIBER-ONC, Madrid, Spain. · Institute of Cancer Research, London, UK. · Institut Paoli-Calmettes, Marseille, France. · St. Augustinus Hospital, Antwerp, Belgium. · Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium. · Cedars-Sinai Medical Center, Los Angeles, CA, USA. · Medical Oncology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain. · Novartis Pharma S.A.S, Rueil-Malmaison, France. · Novartis Pharma AG, Basel, Switzerland. · Novartis Healthcare Pvt. Ltd., Hyderabad, India. · Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, France. · Pubmed 28282611
  • Department of Drug Development, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · Department of Medical Oncology, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA. · Comprehensive Cancer Center Yale School of Medicine, New Haven. · Sanofi Genzyme, Cambridge, USA. · Pubmed 28039155
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Cancer Medicine, Institute Gustave Roussy, Villejuif, France. · Department of Oncology, University of Paris, Paris, France. · Janssen Oncology Research & Development, Raritan, New Jersey. · Janssen Research & Development, Menlo Park, California. · Millennium Pharmaceuticals Inc., Cambridge, Massachusetts. · Department of Surgery, University of Montréal, Montréal, Québec, Canada. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Medicine, Weill Cornell Medical College, New York, New York. · Pubmed 27678453
  • Department of Cancer Medicine, Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France. · The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Medivation, Inc, San Francisco, California. · Memorial Sloan-Kettering Cancer Center, New York, New York. · Pubmed 27648814
  • Health Technology and Services Research Department, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. Electronic address: · Formal Methods and Tools Group, Faculty of Electrical Engineering, Mathematics and Computer Science, University of Twente, Enschede, The Netherlands. · Clinical Studies Department, The Institute of Cancer Research, London, UK. · Health Technology and Services Research Department, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. · Prostate Cancer Unit, The Institute of Cancer Research, London, UK. · Pubmed 29241901
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States. · Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States. · Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain. · The Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States. · Institute of Applied Physics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute for Biological Interfaces, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institut de Radioprotection et de Sûreté Nucléaire, PRP-ENV/SERIS/LECO, Cadarache, France. · Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom. · Botanical Institute II, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Daniel-Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria. · Institute of Nanotechnology, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Department of Physics, University of Illinois at Urbana-Champaign, Urbana, United States. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · ICREA, Passeig Lluís Companys, Barcelona, Spain. · Pubmed 28826504
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China. · Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. · Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of California at San Francisco, San Francisco, California. · Department of Urology, University of California at San Francisco, San Francisco, California. · Department of Medicine, University of California at San Francisco, San Francisco, California. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom. · Masonic Cancer Center and Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota, Minneapolis, Minnesota. · Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas. · Pubmed 28754673
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · University of California San Francisco, San Francisco, California. · Michigan Centre for Translational Pathology, Ann Arbor, Michigan. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28751446
  • The Royal Marsden NHS Foundation Trust, London, United Kingdom. · The Institute of Cancer Research, London, United Kingdom; Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. · The Institute of Cancer Research, London, United Kingdom. · The Institute of Cancer Research, London, United Kingdom. Electronic address: · Pubmed 28571827
  • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA. · The Institute of Cancer Research, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China. · Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA. · Pubmed 28383660
  • Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas. · Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Urology Institute of Xi'an Jiaotong University, Xi'an, Shaanxi, China. · Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom. · Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. · Freemason's Foundation Centre for Men's Health, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. · Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas. · Pubmed 28302679
  • Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. · Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA. · Department of Clinical Medicine, Rigshospitalet, Copenhagen, Denmark. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Division of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Medical Oncology, Astellas Pharma, Inc., Northbrook, IL, USA. · Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA. · Pubmed 28117385
  • Department of General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Urology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Department of Oral, Maxillo- and Plastic Facial Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Pubmed 28068321
  • University of Alabama at Birmingham, Birmingham, AL, USA. · McMaster University, Hamilton, Ontario, Canada. · Kantonsspital St Gallen, St Gallen, Switzerland. · Mayo Clinic, Rochester, MN, USA. · The Institute of Cancer Research, London, UK. · Pubmed 27670718
  • Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · The Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Epic Sciences, San Diego, CA, USA. · Department Urology, University of Michigan Medical School, Ann Arbor, MI, USA. · Comprehensive Cancer Center, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Pubmed 27539393
  • Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK. Electronic address: · Department of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Cancer Research UK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Department of Radiology, Medical Imaging Research Centre, University Hospitals Leuven, Leuven, Belgium. · Department of Radiology, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA. · Department of Radiology, German Cancer Research Centre Heidelberg (DKFZ), Heidelberg, Germany. · Department of Radiology, European Institute of Oncology, Milan, Italy. · Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. · Department of Urology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Drug Development Unit, Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK. · Pubmed 27317091
  • Institute of Cancer Research, London, United Kingdom · Johns Hopkins University, Baltimore, MD · Tulane University School of Medicine, New Orleans, LA · Pubmed 29083122
2016
  • The Institute of Cancer Research, London, England2The Royal Marsden National Health Service Foundation Trust, London, England. · Pubmed 26719908
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26585581
  • The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK. · Pubmed 27444228
  • Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 26873496
  • Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Academic Urology Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Clinical Academic Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Oncogenetics Team, Division of Cancer Genetics and Epidemiology, The Institute of Cancer Research, London, UK. · Erasmus University Medical Center, Rotterdam, Netherlands. · Departments of Pathology Urology, Comprehensive Cancer Center and Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada. · Division of Medical Oncology, Johns Hopkins Hospital, Baltimore, MA, USA. · Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 26074382
  • Department of Urology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: · Medical Oncology Division, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA. · Department of Urology, Medical University of South Carolina, Charleston, SC, USA. · Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO, USA. · Department of Surgery, University of Montreal Health Center, Montreal, Canada. · Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Urology, Asan Medical Center, Seoul, South Korea. · Department of Urology, Nippon Medical School Hospital, Tokyo, Japan. · Division of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC, USA. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Drug Development Unit, Institute of Cancer Research, Royal Marsden Hospital, London, UK. · Department of Early Clinical Development, Medivation, Inc., San Francisco, CA, USA. · Department of Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Department of Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Astellas Pharma, Inc., Northbrook, IL, USA. · Department of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 27006332
  • Department of Oncology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; Department of Internal Medicine, Stadtspital Waid, Tièchestrasse 99, 8037 Zurich, Switzerland. · Clinical Trial Unit, CTU, University Hospital of Basel, Schanzenstrasse 55, 4031 Basel, Switzerland. · Department of Oncology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland. · Erasmus MC, and ErasmusMC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands. · Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5, UK. · Department of Medicine & Urology, Tulane Cancer Center, 1430 Tulane Avenue, SL-42, New Orleans, 70112 LA, USA. · Pubmed 26829012
  • Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom; and · Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom. · Pubmed 27539840
  • Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Astex Pharmaceuticals, Cambridge, United Kingdom. · Department of Medicine, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. Department of Urology, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 27197266
  • From the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Cancer Therapeutics Division, 15 Cotswold Rd, Sutton SM2 5NG, England. · Pubmed 26807894
  • Department of Radiation Oncology, University of Michigan, Ann Arbor. · Department of Radiation Oncology, University of Michigan, Ann Arbor2Beaumont Hospital - Dearborn, Transitional Year Program, Dearborn, Michigan. · Department of Pathology, University of Michigan, Ann Arbor. · GenomeDx Biosciences Inc, Vancouver, British Columbia, Canada. · Department of Pathology and Laboratory Medicine, Weill Cornell Medical College and New York Presbyterian Hospitals, New York, New York. · Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. · Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Department of Urology, Mayo Clinic, Rochester, Minnesota. · City of Hope, Duarte, California. · Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, England. · Department of Radiation Oncology, University of Michigan, Ann Arbor13Michigan Center for Translational Pathology, University of Michigan, Ann Arbor14Comprehensive Cancer Center, University of Michigan, Ann Arbor. · Pubmed 26746117
  • Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK. · MRC Clinical Trials Unit at UCL, London, UK. Electronic address: · Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK. · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK. · MRC Clinical Trials Unit at UCL, London, UK. · Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds. · Department of Urology, University Hospital, Bern, Switzerland. · Patient rep, MRC Clinical Trials Unit at UCL, London, UK. · Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK. · Kent Oncology Centre, Maidstone Hospital, Maidstone, UK. · Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK. · Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland. · Kantonsspital Graubünden, Chur, Switzerland. · Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK. · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK. · Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK. · Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK. · Department of Oncology, Queen's Hospital, Romford, UK. · Beacon Centre, Musgrove Park Hospital, Taunton, UK. · Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK. · Department of Oncology, Royal Surrey County Hospital, Guildford, UK. · Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK. · Department of Oncology, Western General Hospital, Edinburgh, UK. · Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK. · Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK. · Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK. · Department of Oncology, Churchill Hospital, Oxford, UK. · Department of Oncology, Sussex Cancer Centre, Brighton, UK. · Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK. · Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK. · Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK. · Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK. · Department of Oncology, Southend & Basildon Hospitals, Essex, UK. · The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK. · Pubmed 26719232
  • Warwick Medical School, University of Warwick, Coventry, United Kingdom2University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, United Kingdom. · Medical Research Council Clinical Trials Unit, University College, London, United Kingdom. · Department of Urology, Christie NHS Foundation Trust, Manchester, United Kingdom. · Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Velindre Hospital, Cardiff, United Kingdom. · Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. · Royal Preston Hospital, Preston, United Kingdom. · Cantonal Hospital St Gallen, St Gallen, Switzerland. · Greater Manchester Group, Manchester, United Kingdom. · Leeds Beckett University, Leeds, United Kingdom. · Belfast City Hospital, Belfast, United Kingdom. · Singleton Hospital, Swansea, United Kingdom. · Royal Shrewsbury Hospital, Shrewsbury, United Kingdom. · Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. · CCO Liverpool Warrington Aintree, Liverpool, United Kingdom. · Pubmed 26606329
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 27330057
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY · Memorial Sloan Kettering Cancer Center, New York, NY. · Janssen Research & Development, Menlo Park, CA. · Janssen Research & Development, San Diego, CA. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26598756
2015
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26065613
  • Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 25251387
  • Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Guys and St Thomas' Hospital, London, UK. · Department of Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Department of Early Clinical Development, Medivation, San Francisco, CA, USA. · Health Economics and Outcomes Research, Astellas Pharma Europe, Leiden, Netherlands. · Department of Medical Affairs, Medivation, San Francisco, CA, USA. · Astellas Pharma Global Development, Northbrook, IL, USA. · Consulting, Quintiles, Hoofddorp, Netherlands. · Consulting, Quintiles, Barcelona, Spain; Department of Public Health, University of Barcelona, Barcelona, Spain. · Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 25888263
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · University of Montréal, Montréal, Québec, Canada. · Radboud University Medical Centre, Nijmegen, Netherlands. · San Camillo and Forlanini Hospitals, Rome, Italy. · Charité Berlin, Berlin, Germany. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia. · The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, United Kingdom. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Beerse, Belgium. · Janssen Research & Development, Raritan, NJ, USA. · Janssen Research & Development, Menlo Park, CA, USA. · Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Pubmed 25601341
  • The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The University of Texas MD Anderson Cancer Center, Houston, Texas. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada. · Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. · Ziekenhuisnetwerk Antwerpen-Middelheim Oncology Clinic, Antwerp, Belgium. · VU University Medical Center, Amsterdam, the Netherlands. · Janssen Research and Development, Spring House, Pennsylvania. · Janssen Research and Development, Menlo Park, California. · Janssen Research and Development, Los Angeles, California. · Janssen Research and Development, San Diego, California. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. · Pubmed 25593303
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK. · Department of Medical Oncology, Kantonsspital St Gallen, St Gallen, Switzerland. · Department of Clinical Oncology, Bristol Haematology and Oncology Centre, Bristol, UK. · Oncology, Sanofi Oncology, Cambridge. · Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology, Tulane University, New Orleans, USA. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK · Pubmed 25538172
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Department of Medical Cell BioPhysics, University of Twente, Enschede, the Netherlands. · Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26567358
  • Centre for Integrative Biology, University of Trento, Trento 38123, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. · The Institute of Cancer Research, London SW7 3RP, UK. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · Centre for Integrative Biology, University of Trento, Trento 38123, Italy. Institute for Computational Biomedicine, Weill Cornell Medicine, NY 10021, USA. Institute for Precision Medicine, Weill Cornell Medicine, NY 10021, USA. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Pubmed 26537258
  • Genentech Inc., South San Francisco, CA, USA. · The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, UK. · The Institute of Cancer Research, London, UK. · Epic Sciences Inc., San Diego, CA, USA. · Core Diagnostics, Palo Alto, CA, USA. · Pubmed 26379078
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States. · Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom. · The Royal Marsden, London, United Kingdom. · Department of Urology, Weill Cornell Medical College, New York, United States. · Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States. · Centre for Integrative Biology, University of Trento, Trento, Italy. · Department of Surgery, Weill Cornell Medical College, New York, United States. · HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States. · Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States. · Department of Medicine, Weill Cornell Medical College, New York, United States. · Pubmed 26374986
  • Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA; Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA. · Cancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London SM2 5NG, UK. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA. · Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Interventional Radiology, Department of Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. · Department of Musculoskeletal Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA. · Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Radiology, University of Washington, Seattle, WA 98109, USA. · Department of Pathology, University of Washington Medical Center, Seattle, WA 98109, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Laboratory of Computational Oncology, CIBIO, Centre for Integrative Biology, University of Trento, 38123 Mattarello TN, Italy. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Division of Interventional Radiology, Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Department of Physiology & Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA. · The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: · Pubmed 26000489
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK. · Department of Medical Cell BioPhysics, MIRA Institute, University of Twente, 7522ND, Enschede, The Netherlands. · 1] Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK [2] Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK. · Pubmed 25719830
  • Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 25555314
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 25454616
  • University of Warwick, Coventry, UK. Electronic address: · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Queen Alexandra Hospital, Portsmouth, UK. · Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Hospital, Northwood, Middlesex, UK. · University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Royal Surrey County Hospital, Guildford, UK. · Velindre Hospital, Cardiff, UK. · Western General Hospital, Edinburgh, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Kantonsspital Graübunden, Chur, Switzerland. · Department of Urology, University Hospital, Bern, Switzerland. · Pubmed 25301760
  • Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: · Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Ulm University Medical Centre, Ulm, Germany. · Urologische Klinik und Poliklinik, Technische Universität München, Munich, Germany. · Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Department of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany. · Department of Urology, Muenster University Medical Centre, Muenster, Germany. · Pubmed 25108579
2014
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · University of Bern, Bern, Switzerland. · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Department of Urology, University Hospital, Bern, Switzerland. · Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Patient representative, Stockton-on-Tees, UK. · Patient representative, Northampton, UK. · University of Warwick, Warwick, UK. · Pubmed 24985962
  • From the Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 24857103
  • Prostate Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Clinical Studies, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Pubmed 24840076
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. Electronic address: · Pubmed 24418724
  • The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 24685433
  • Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · University of Western Sydney School of Medicine, Penrith, Australia. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Hematology & Oncology Clinics of Australia, Brisbane, Australia. · Sarah Cannon Research Institute, Nashville, TN, USA. · Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA. · Cross Cancer Institute, Edmonton, Alberta, Canada. · Laval University, Québec City, Québec, Canada. · University Hospital Leuven, Leuven, Belgium. · Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Raritan, NJ, USA. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. · Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Janssen Research & Development, Menlo Park, CA, USA. · CRCHUM, University of Montréal, Montréal, Québec, Canada. · Pubmed 24647231
  • Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 24411987
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Guy's and St. Thomas' NHS Foundation Trust, Great Maze Pond, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 24074764
  • The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. · Guy's and St. Thomas NHS Foundation Trust, United Kingdom. · The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: · Pubmed 24433842
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Academic Urology Unit, Sutton, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK. · Pubmed 24300975
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 24295792
2012
  • Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK. · Pubmed 21903605
2011
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 21612468
2010
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Pubmed 20888992
2008
  • Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom. · Pubmed 18829513
2017
  • Mario Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Anne-Claire Hardy-Bessard, Centre Armoricain d'Oncologie, Centre Armoricain de Radiothérapie, d'Imagerie Médicale et d'Oncologie-Hôpital Privé Des Côtes d'Armor, Plérin; Loïc Mourey, Institut Claudius Regaud, l'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Mustapha Chadjaa, Sanofi, Vitry-sur-Seine, France; Choung Soo Kim, Asan Medical Center, Seoul, South Korea; Lajos Géczi, National Institute of Oncology, Budapest, Hungary; Daniel Ford, City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham; Johann de Bono, Prostate Cancer Targeted Therapy Team, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom; Joan Carles, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Phillip Parente, Eastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, Victoria, Australia; Albert Font, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Gabriel Kacso, Iuliu Hatieganu Medical University, Amethyst Radiology Therapeutic Center, Cluj, Romania; Wenping Zhang, Sanofi, Bridgewater, NJ; and John Bernard, Sanofi, Cambridge, MA. · Pubmed 28809610
  • From the Institute of Cancer and Genomic Sciences, University of Birmingham (N.D.J.), and University Hospital Birmingham (A.Z.), Birmingham, the Institute of Cancer Research (J.S.B., D.P.D., G.A.), Medical Research Council Clinical Trials Unit at University College London (M.R. Spears, C.L.A., C.G., C.B., M.K.B.P., M.R. Sydes), King's College London and Guy's and St. Thomas' NHS Foundation Trust (S.C.), and Royal Marsden NHS Foundation Trust (C.C.P.), London, Salford Royal NHS Foundation Trust, Salford (N.W.C.), Cardiff University School of Medicine (M.D.M.) and Velindre Cancer Centre (J.F.L.), Cardiff, Gloucestershire Royal Hospital (A.W.S.R.) and Gloucestershire Hospitals NHS Foundation Trust (J.B.), Gloucester, University of Glasgow, Glasgow (R.J.J., J.M.R.), St. James's University Hospital, Leeds (W.R.C.), University Hospital of North-Midlands, Stoke-on-Trent (F.A.), Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter (S.A.), Rosemere Cancer Centre, Royal Preston Hospital, Preston (A.J.B.), Dorset Cancer Centre, Poole Hospital, Poole (S.B.), Royal Derby Hospital, Derby (P.C.), Weston Park Hospital, Sheffield (C.F.), Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth (J.G.), Musgrove Park Hospital, Taunton (E.G.), Hull and East Yorkshire Hospitals NHS Trust, Hull (M.H.), Mount Vernon Cancer Centre, Northwood (P.J.H.), Clatterbridge Cancer Centre, Wirral (Z.I.M.), Brighton and Sussex University Hospitals NHS Trust (F.M.) and Sussex Cancer Centre, Royal Sussex County Hospital (A.R.), Brighton, NHS Highland, Inverness (N.M.), Royal Surrey County Hospital, Guildford (J.M.-K.), Northern Ireland Cancer and Queens University, Belfast (J.O.), Lancashire Teaching Hospitals NHS Trust, Preston (O.P.), Churchill Hospital, Oxford (A.P.), Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury (N.N.S.), East Kent Hospitals NHS Trust, Canterbury (C.T.), Swansea University College of Medicine, Swansea (J. Wagstaff), and Christie NHS Foundation Trust, Manchester (J. Wylie) - all in the United Kingdom; and the Department of Medical Oncology, Kantonsspital St. Gallen, St. Gallen (S.G.), and University Hospital of Lausanne, Lausanne (D.R.B.) - both in Switzerland. Two of the authors (D.M., R.M.) were unaffiliated lay members of the STAMPEDE investigators. · Pubmed 28578639
2016
  • From the *Prostate Cancer Unit, Spanish National Cancer Research Centre (CNIO); and †HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain; ‡Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research; and §Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; and ∥CNIO-IBIMA Genitourinary Cancer Unit at Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Pubmed 27749330
  • From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.). · Pubmed 27433846
  • Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Pubmed 26951312
2015
  • From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.). · Pubmed 26510020
  • Prostate Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 25920479
  • Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25800753
  • Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25624432
  • Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Stephane Oudard, Université Paris Descartes, Paris, France; Robert Jones, Institute of Cancer Sciences, University of Glasgow, Glasgow; Johann De Bono, The Institute of Cancer Research, London, United Kingdom; Eleni Efstathiou, University of Athens Medical School, Athens; George Fountzilas, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Fred Saad, University of Montreal Hospital Center, Montreal, Canada; Ronald de Wit, Erasmus University Medical Center, Rotterdam, the Netherlands; Felipe Melo Cruz, ABC Foundation School of Medicine, Santo André; Flavio Carcano, Hospital de Cancer de Barretos, Barretos, Brazil; Albertas Ulys, Institut of Oncology, Vilnius University, Vilnius, Lithuania; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; David Agus, University of Southern California, Los Angeles, CA; Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Shih-Yuan Lee, Bindu Tejura, Niels Borgstein, Takeda Pharmaceuticals International; Iain J. Webb, Millennium: The Takeda Oncology Company, Cambridge, MA; Robert Dreicer, Cleveland Clinic, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain. · Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Stephane Oudard, Université Paris Descartes, Paris, France; Robert Jones, Institute of Cancer Sciences, University of Glasgow, Glasgow; Johann De Bono, The Institute of Cancer Research, London, United Kingdom; Eleni Efstathiou, University of Athens Medical School, Athens; George Fountzilas, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Fred Saad, University of Montreal Hospital Center, Montreal, Canada; Ronald de Wit, Erasmus University Medical Center, Rotterdam, the Netherlands; Felipe Melo Cruz, ABC Foundation School of Medicine, Santo André; Flavio Carcano, Hospital de Cancer de Barretos, Barretos, Brazil; Albertas Ulys, Institut of Oncology, Vilnius University, Vilnius, Lithuania; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; David Agus, University of Southern California, Los Angeles, CA; Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Shih-Yuan Lee, Bindu Tejura, Niels Borgstein, Takeda Pharmaceuticals International; Iain J. Webb, Millennium: The Takeda Oncology Company, Cambridge, MA; Robert Dreicer, Cleveland Clinic, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain. · Pubmed 25624429
  • Section of Medicine, The Institute of Cancer Research, London, UK. · Pubmed 25041380
2014
  • Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 24390422
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 24108540
  • Authors' Affiliations: Royal Marsden NHS Foundation Trust and The Institute of Cancer Research UK, Sutton; Institut Català d'Oncologia, L'Hospitalet, Barcelona; University of Surrey, Surrey, United Kingdom; Yale University Cancer Center, New Haven; Centre Hospitalier de l'Universite de Montreal, Montreal; A Coruña University Hospital, A Coruña, Spain; Kantonsspital St. Gallen, St. Gallen, Switzerland; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Pfizer Inc, Groton, Connecticut; and Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. · Pubmed 24536060
  • Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Sciences, Institute of Cancer Research/Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK. · Pubmed 24490608
2013
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 24188261
  • Institute of Cancer Research, London, United Kingdom. · Pubmed 23337755
  • Division of Cancer Therapeutics, Signal Transduction & Molecular Pharmacology and Clinical Pharmacology & Trials Team, Institute of Cancer Research, Sutton, SM25NG, United Kingdom. · Pubmed 23020876
  • 1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK [2] Memorial Sloan-Kettering Cancer Center (MSKCC) and Weill Cornell Medical College, Center for Prostate and Urologic Cancers, New York, NY, USA. · Pubmed 24169353
  • Affiliations of authors: Department of Biostatistics and Bioinformatics, (SH, C-YL, EK), and Alliance Statistics and Data Center (SH), Duke University, Durham, NC; Departments of Medicine and Urology, University of California-San Francisco, San Francisco, CA (EJS); Division of Medical Oncology, Duke Prostate Center and the Duke Cancer Institute, Durham, NC (AJA); Departments of Medical Oncology and Urology, Yale University Cancer Center, New Haven, CT (DP); Department of Medical Oncology, San Camillo and Forlanini Hospital, Rome, Italy (CNS); Sanofi, Malvern, PA (LS); Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France (SO); Department of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, Surrey, United Kingdom (JdB); Urology Department, Tulane Cancer Center, New Orleans, LA (OS). · Pubmed 24136890
  • The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 23810788
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23807167
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23928659
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23313031
2012
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 23098113
  • Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 22621691
  • Drug Development Unit, The Institute of Cancer Research, ICR and Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, Sutton, Surrey, SM25PT, UK. · Pubmed 22373838
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 22229405
  • Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom. · Pubmed 21986558
  • The Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK. · Pubmed 22170708
  • The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 22460813
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Pubmed 22411952
2011
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21943974
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 21826082
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21680542
  • Section of Medicine, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 21372223
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK. · Pubmed 21710270
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK. · Pubmed 21498309
2010
  • The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 20628389
  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 20159823
  • Drug Development Unit, Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 19608618
  • Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. · Pubmed 20177423
  • The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Section of Medicine, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 20868208
2009
  • Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom. · Pubmed 19638457
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Pubmed 19509232
  • The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 19962664
  • The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Pubmed 19339269
  • Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK. · Pubmed 19040532
2008
  • Institute of Cancer Research, Male Urological Cancer Research Centre, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. · Pubmed 18594527
  • Prostate Stem Cell Laboratory, Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 18398820
  • Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey SM2 5NG, UK. · Pubmed 18165275
Probable:    Royal Marsden Hospital and Trust      
2018
  • Menarini Silicon Biosystems spa, Bologna, Italy. · Department of General, Visceral and Pediatric Surgery, Medical Faculty, University Hospital of the Heinrich- Heine-University Düsseldorf, Düsseldorf, Germany. · Unità Operativa di Oncologia Medica, Policlinico Sant'Orsola - Malpighi, Bologna, Italy. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Pubmed 29494651
2017
  • Eastern Health & Monash University, Melbourne, Australia. · Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland and University of Bern, Switzerland. · Europa Uomo Prostate Patients, Clayhall Ilford, UK. · The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, UK. · Knight Cancer Institute, Oregon Health & Science University, Portland, USA. · BC Cancer Agency and University of British Columbia, Vancouver, Canada. · Department of Medical Oncology, Guy's Hospital, London, UK. · Monash University Eastern Health Clinical School, Melbourne, Australia. · Division of Haematology/Oncology, Columbia University Medical Center, New York. · Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. · Department of Cancer Medicine, Institut Paoli Calmette, Marseille, France. · Fred Hutchinson Cancer Research Center, University of Washington, Seattle. · Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA. · Clinical Oncology Unit, Queen Elizabeth Hospital Birmingham, University of Birmingham, Birmingham, UK. · Department of Clinical Therapeutics, David H. Koch Centre, Alexandra Hospital, University of Athens, Athens, Greece. · Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, USA. · Clinical Oncology Academic Unit, Royal Marsden NHS Foundation Trust, London, UK. · Clinical Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), San Francisco, USA. · Department of Surgery, Centre Hospitalier de Université de Montréal, Montreal, Canada. · Department of Medicine and Urology, Tulane Cancer Center, New Orleans. · Department of Medicine, University of California, San Francisco, USA. · Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. · Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, USA. · Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada. · Cliniques Universitaires Saint Luc, Brussels, Belgium. · Pubmed 28838209
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28419178
  • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 28233594
  • Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28000989
  • The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. · Pubmed 27753448
  • Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Department of Urology, Weill Cornell Medicine, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. · Sheffield Institute for Nucleic Acids, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain; Medical Oncology Department, CNIO-IBIMA Genitourinary Cancer Unit, Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. · Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 27590317
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. · Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, United Kingdom. · Academic Urology Unit, Royal Marsden Hospital, Sutton, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. Electronic address: · Pubmed 28606735
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · The University of Michigan, Ann Arbor, Michigan. · Peter MacCallum Cancer Centre, Melbourne, Australia. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28450425
  • OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Electronic address: · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Cancer Medicine, Gustave Roussy, University of Paris-Sud, Villejuif, France. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium. · Department of Medical Oncology, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. · Department of Medicine, University of Colorado School of Medicine, Aurora, CO. · Department of Medical Oncology, USC Norris Cancer Hospital, Keck Medical Center of USC, Los Angeles, CA. · Department of Biostatistics, Astellas Pharma Europe, BV, Leiden, Netherlands. · Department of Biostatistics, Medivation, Inc, San Francisco, CA. · Department of Clinical Development, Medivation, Inc, San Francisco, CA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. · Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA. · Pubmed 28344102
  • Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. Electronic address: · Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Trial Architecture Consulting, Washington, DC, USA. · Centre Antoine Lacassagne, Nice, France. · Florida Cancer Specialists, Fort Myers, FL, USA. · Department of Urology, Tübingen, Germany. · Institut Paoli Calmette, Department of Cancer Medicine, Marseille, France. · Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany. · University of Tübingen, Tübingen, Germany. · Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada. · Durham Regional Cancer Centre, Oshawa, ON, Canada. · Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. · OncoGenex Pharmaceuticals, Bothell, WA, USA. · Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Pubmed 28283282
  • Department of Drug Development, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · Department of Medical Oncology, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA. · Comprehensive Cancer Center Yale School of Medicine, New Haven. · Sanofi Genzyme, Cambridge, USA. · Pubmed 28039155
  • From the Inst of Cancer Research and Royal Marsden NHS Foundation Trust, Cancer Therapeutics Div, 15 Cotswold Rd, Sutton SM2 5NG, England. · Pubmed 27875103
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Cancer Medicine, Institute Gustave Roussy, Villejuif, France. · Department of Oncology, University of Paris, Paris, France. · Janssen Oncology Research & Development, Raritan, New Jersey. · Janssen Research & Development, Menlo Park, California. · Millennium Pharmaceuticals Inc., Cambridge, Massachusetts. · Department of Surgery, University of Montréal, Montréal, Québec, Canada. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Medicine, Weill Cornell Medical College, New York, New York. · Pubmed 27678453
  • Department of Cancer Medicine, Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France. · The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Medivation, Inc, San Francisco, California. · Memorial Sloan-Kettering Cancer Center, New York, New York. · Pubmed 27648814
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States. · Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States. · Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain. · The Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States. · Institute of Applied Physics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute for Biological Interfaces, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institut de Radioprotection et de Sûreté Nucléaire, PRP-ENV/SERIS/LECO, Cadarache, France. · Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom. · Botanical Institute II, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Daniel-Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria. · Institute of Nanotechnology, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Department of Physics, University of Illinois at Urbana-Champaign, Urbana, United States. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · ICREA, Passeig Lluís Companys, Barcelona, Spain. · Pubmed 28826504
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China. · Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. · Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of California at San Francisco, San Francisco, California. · Department of Urology, University of California at San Francisco, San Francisco, California. · Department of Medicine, University of California at San Francisco, San Francisco, California. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom. · Masonic Cancer Center and Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota, Minneapolis, Minnesota. · Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas. · Pubmed 28754673
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · University of California San Francisco, San Francisco, California. · Michigan Centre for Translational Pathology, Ann Arbor, Michigan. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28751446
  • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA. · The Institute of Cancer Research, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China. · Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA. · Pubmed 28383660
  • Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. · Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA. · Department of Clinical Medicine, Rigshospitalet, Copenhagen, Denmark. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Division of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Medical Oncology, Astellas Pharma, Inc., Northbrook, IL, USA. · Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA. · Pubmed 28117385
  • Department of General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Urology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Department of Oral, Maxillo- and Plastic Facial Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Pubmed 28068321
  • Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · The Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Epic Sciences, San Diego, CA, USA. · Department Urology, University of Michigan Medical School, Ann Arbor, MI, USA. · Comprehensive Cancer Center, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Pubmed 27539393
  • Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK. Electronic address: · Department of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Cancer Research UK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Department of Radiology, Medical Imaging Research Centre, University Hospitals Leuven, Leuven, Belgium. · Department of Radiology, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA. · Department of Radiology, German Cancer Research Centre Heidelberg (DKFZ), Heidelberg, Germany. · Department of Radiology, European Institute of Oncology, Milan, Italy. · Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. · Department of Urology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Drug Development Unit, Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK. · Pubmed 27317091
2016
  • The Institute of Cancer Research, London, England2The Royal Marsden National Health Service Foundation Trust, London, England. · Pubmed 26719908
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26585581
  • The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK. · Pubmed 27444228
  • Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 26873496
  • Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Academic Urology Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Clinical Academic Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Oncogenetics Team, Division of Cancer Genetics and Epidemiology, The Institute of Cancer Research, London, UK. · Erasmus University Medical Center, Rotterdam, Netherlands. · Departments of Pathology Urology, Comprehensive Cancer Center and Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada. · Division of Medical Oncology, Johns Hopkins Hospital, Baltimore, MA, USA. · Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 26074382
  • Department of Urology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: · Medical Oncology Division, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA. · Department of Urology, Medical University of South Carolina, Charleston, SC, USA. · Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO, USA. · Department of Surgery, University of Montreal Health Center, Montreal, Canada. · Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Urology, Asan Medical Center, Seoul, South Korea. · Department of Urology, Nippon Medical School Hospital, Tokyo, Japan. · Division of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC, USA. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Drug Development Unit, Institute of Cancer Research, Royal Marsden Hospital, London, UK. · Department of Early Clinical Development, Medivation, Inc., San Francisco, CA, USA. · Department of Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Department of Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Astellas Pharma, Inc., Northbrook, IL, USA. · Department of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 27006332
  • Department of Oncology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; Department of Internal Medicine, Stadtspital Waid, Tièchestrasse 99, 8037 Zurich, Switzerland. · Clinical Trial Unit, CTU, University Hospital of Basel, Schanzenstrasse 55, 4031 Basel, Switzerland. · Department of Oncology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland. · Erasmus MC, and ErasmusMC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands. · Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5, UK. · Department of Medicine & Urology, Tulane Cancer Center, 1430 Tulane Avenue, SL-42, New Orleans, 70112 LA, USA. · Pubmed 26829012
  • Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Astex Pharmaceuticals, Cambridge, United Kingdom. · Department of Medicine, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. Department of Urology, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 27197266
  • From the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Cancer Therapeutics Division, 15 Cotswold Rd, Sutton SM2 5NG, England. · Pubmed 26807894
  • Department of Radiation Oncology, University of Michigan, Ann Arbor. · Department of Radiation Oncology, University of Michigan, Ann Arbor2Beaumont Hospital - Dearborn, Transitional Year Program, Dearborn, Michigan. · Department of Pathology, University of Michigan, Ann Arbor. · GenomeDx Biosciences Inc, Vancouver, British Columbia, Canada. · Department of Pathology and Laboratory Medicine, Weill Cornell Medical College and New York Presbyterian Hospitals, New York, New York. · Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. · Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Department of Urology, Mayo Clinic, Rochester, Minnesota. · City of Hope, Duarte, California. · Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, England. · Department of Radiation Oncology, University of Michigan, Ann Arbor13Michigan Center for Translational Pathology, University of Michigan, Ann Arbor14Comprehensive Cancer Center, University of Michigan, Ann Arbor. · Pubmed 26746117
  • Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK. · MRC Clinical Trials Unit at UCL, London, UK. Electronic address: · Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK. · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK. · MRC Clinical Trials Unit at UCL, London, UK. · Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds. · Department of Urology, University Hospital, Bern, Switzerland. · Patient rep, MRC Clinical Trials Unit at UCL, London, UK. · Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK. · Kent Oncology Centre, Maidstone Hospital, Maidstone, UK. · Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK. · Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland. · Kantonsspital Graubünden, Chur, Switzerland. · Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK. · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK. · Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK. · Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK. · Department of Oncology, Queen's Hospital, Romford, UK. · Beacon Centre, Musgrove Park Hospital, Taunton, UK. · Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK. · Department of Oncology, Royal Surrey County Hospital, Guildford, UK. · Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK. · Department of Oncology, Western General Hospital, Edinburgh, UK. · Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK. · Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK. · Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK. · Department of Oncology, Churchill Hospital, Oxford, UK. · Department of Oncology, Sussex Cancer Centre, Brighton, UK. · Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK. · Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK. · Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK. · Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK. · Department of Oncology, Southend & Basildon Hospitals, Essex, UK. · The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK. · Pubmed 26719232
  • Warwick Medical School, University of Warwick, Coventry, United Kingdom2University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, United Kingdom. · Medical Research Council Clinical Trials Unit, University College, London, United Kingdom. · Department of Urology, Christie NHS Foundation Trust, Manchester, United Kingdom. · Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Velindre Hospital, Cardiff, United Kingdom. · Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. · Royal Preston Hospital, Preston, United Kingdom. · Cantonal Hospital St Gallen, St Gallen, Switzerland. · Greater Manchester Group, Manchester, United Kingdom. · Leeds Beckett University, Leeds, United Kingdom. · Belfast City Hospital, Belfast, United Kingdom. · Singleton Hospital, Swansea, United Kingdom. · Royal Shrewsbury Hospital, Shrewsbury, United Kingdom. · Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. · CCO Liverpool Warrington Aintree, Liverpool, United Kingdom. · Pubmed 26606329
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 27330057
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY · Memorial Sloan Kettering Cancer Center, New York, NY. · Janssen Research & Development, Menlo Park, CA. · Janssen Research & Development, San Diego, CA. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26598756
2015
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26065613
  • Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 25563847
  • Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 25251387
  • Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Guys and St Thomas' Hospital, London, UK. · Department of Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Department of Early Clinical Development, Medivation, San Francisco, CA, USA. · Health Economics and Outcomes Research, Astellas Pharma Europe, Leiden, Netherlands. · Department of Medical Affairs, Medivation, San Francisco, CA, USA. · Astellas Pharma Global Development, Northbrook, IL, USA. · Consulting, Quintiles, Hoofddorp, Netherlands. · Consulting, Quintiles, Barcelona, Spain; Department of Public Health, University of Barcelona, Barcelona, Spain. · Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 25888263
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · University of Montréal, Montréal, Québec, Canada. · Radboud University Medical Centre, Nijmegen, Netherlands. · San Camillo and Forlanini Hospitals, Rome, Italy. · Charité Berlin, Berlin, Germany. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia. · The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, United Kingdom. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Beerse, Belgium. · Janssen Research & Development, Raritan, NJ, USA. · Janssen Research & Development, Menlo Park, CA, USA. · Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Pubmed 25601341
  • The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The University of Texas MD Anderson Cancer Center, Houston, Texas. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada. · Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. · Ziekenhuisnetwerk Antwerpen-Middelheim Oncology Clinic, Antwerp, Belgium. · VU University Medical Center, Amsterdam, the Netherlands. · Janssen Research and Development, Spring House, Pennsylvania. · Janssen Research and Development, Menlo Park, California. · Janssen Research and Development, Los Angeles, California. · Janssen Research and Development, San Diego, California. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. · Pubmed 25593303
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK. · Department of Medical Oncology, Kantonsspital St Gallen, St Gallen, Switzerland. · Department of Clinical Oncology, Bristol Haematology and Oncology Centre, Bristol, UK. · Oncology, Sanofi Oncology, Cambridge. · Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology, Tulane University, New Orleans, USA. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK · Pubmed 25538172
  • Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: · Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weil Cornell Medical College, New York, NY, USA. · Genitourinary Oncology Program, Massachusetts General Hospital, Boston, MA, USA. · Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA. · Clinical Development, Exelixis, Inc., South San Francisco, CA, USA. · Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA. · Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. · Genitourinary Medical Oncology, Duke University Medical Center, Durham, NC, USA. · Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. · Urologic Surgery and Oncology, University of California San Francisco, San Francisco, CA, USA. · Tulane Cancer Center, Tulane University, New Orleans, LA, USA. · Pinnacle Oncology Hematology, Scottsdale, AZ, USA. · Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. · Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, UK. · Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. · Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 24631409
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Department of Medical Cell BioPhysics, University of Twente, Enschede, the Netherlands. · Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26567358
  • Centre for Integrative Biology, University of Trento, Trento 38123, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. · The Institute of Cancer Research, London SW7 3RP, UK. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · Centre for Integrative Biology, University of Trento, Trento 38123, Italy. Institute for Computational Biomedicine, Weill Cornell Medicine, NY 10021, USA. Institute for Precision Medicine, Weill Cornell Medicine, NY 10021, USA. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Pubmed 26537258
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States. · Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom. · The Royal Marsden, London, United Kingdom. · Department of Urology, Weill Cornell Medical College, New York, United States. · Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States. · Centre for Integrative Biology, University of Trento, Trento, Italy. · Department of Surgery, Weill Cornell Medical College, New York, United States. · HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States. · Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States. · Department of Medicine, Weill Cornell Medical College, New York, United States. · Pubmed 26374986
  • Icahn Institute for Genomics and Multiscale Biology, New York, NY, 10029, USA. · Department of Genetics and Genomic Sciences, New York, USA. · The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. · Department of Urology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. · Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. · Prostate Cancer clinical research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. · Medical Oncology Deparment, CNIO-IBIMA Genitourinary Cancer Clinical Research Unit, hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain. · Icahn Institute for Genomics and Multiscale Biology, New York, NY, 10029, USA. · Department of Genetics and Genomic Sciences, New York, USA. · The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. · The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. · Pubmed 26297150
  • Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA; Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA. · Cancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London SM2 5NG, UK. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA. · Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Interventional Radiology, Department of Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. · Department of Musculoskeletal Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA. · Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Radiology, University of Washington, Seattle, WA 98109, USA. · Department of Pathology, University of Washington Medical Center, Seattle, WA 98109, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Laboratory of Computational Oncology, CIBIO, Centre for Integrative Biology, University of Trento, 38123 Mattarello TN, Italy. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Division of Interventional Radiology, Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Department of Physiology & Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA. · The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: · Pubmed 26000489
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK. · Department of Medical Cell BioPhysics, MIRA Institute, University of Twente, 7522ND, Enschede, The Netherlands. · 1] Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK [2] Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK. · Pubmed 25719830
  • Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 25555314
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 25454616
  • University of Warwick, Coventry, UK. Electronic address: · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Queen Alexandra Hospital, Portsmouth, UK. · Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Hospital, Northwood, Middlesex, UK. · University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Royal Surrey County Hospital, Guildford, UK. · Velindre Hospital, Cardiff, UK. · Western General Hospital, Edinburgh, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Kantonsspital Graübunden, Chur, Switzerland. · Department of Urology, University Hospital, Bern, Switzerland. · Pubmed 25301760
  • Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: · Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Ulm University Medical Centre, Ulm, Germany. · Urologische Klinik und Poliklinik, Technische Universität München, Munich, Germany. · Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Department of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany. · Department of Urology, Muenster University Medical Centre, Muenster, Germany. · Pubmed 25108579
2014
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · University of Bern, Bern, Switzerland. · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Department of Urology, University Hospital, Bern, Switzerland. · Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Patient representative, Stockton-on-Tees, UK. · Patient representative, Northampton, UK. · University of Warwick, Warwick, UK. · Pubmed 24985962
  • From the Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 24857103
  • Prostate Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Clinical Studies, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Pubmed 24840076
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. Electronic address: · Pubmed 24418724
  • The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 24685433
  • Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · University of Western Sydney School of Medicine, Penrith, Australia. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Hematology & Oncology Clinics of Australia, Brisbane, Australia. · Sarah Cannon Research Institute, Nashville, TN, USA. · Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA. · Cross Cancer Institute, Edmonton, Alberta, Canada. · Laval University, Québec City, Québec, Canada. · University Hospital Leuven, Leuven, Belgium. · Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Raritan, NJ, USA. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. · Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Janssen Research & Development, Menlo Park, CA, USA. · CRCHUM, University of Montréal, Montréal, Québec, Canada. · Pubmed 24647231
  • Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 24411987
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Guy's and St. Thomas' NHS Foundation Trust, Great Maze Pond, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 24074764
  • The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. · Guy's and St. Thomas NHS Foundation Trust, United Kingdom. · The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: · Pubmed 24433842
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Academic Urology Unit, Sutton, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK. · Pubmed 24300975
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 24295792
2012
  • Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK. · Pubmed 21903605
2011
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 21612468
2010
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Pubmed 20888992
2008
  • Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom. · Pubmed 18829513
2017
  • Mario Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Anne-Claire Hardy-Bessard, Centre Armoricain d'Oncologie, Centre Armoricain de Radiothérapie, d'Imagerie Médicale et d'Oncologie-Hôpital Privé Des Côtes d'Armor, Plérin; Loïc Mourey, Institut Claudius Regaud, l'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Mustapha Chadjaa, Sanofi, Vitry-sur-Seine, France; Choung Soo Kim, Asan Medical Center, Seoul, South Korea; Lajos Géczi, National Institute of Oncology, Budapest, Hungary; Daniel Ford, City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham; Johann de Bono, Prostate Cancer Targeted Therapy Team, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom; Joan Carles, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Phillip Parente, Eastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, Victoria, Australia; Albert Font, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Gabriel Kacso, Iuliu Hatieganu Medical University, Amethyst Radiology Therapeutic Center, Cluj, Romania; Wenping Zhang, Sanofi, Bridgewater, NJ; and John Bernard, Sanofi, Cambridge, MA. · Pubmed 28809610
  • From the Institute of Cancer and Genomic Sciences, University of Birmingham (N.D.J.), and University Hospital Birmingham (A.Z.), Birmingham, the Institute of Cancer Research (J.S.B., D.P.D., G.A.), Medical Research Council Clinical Trials Unit at University College London (M.R. Spears, C.L.A., C.G., C.B., M.K.B.P., M.R. Sydes), King's College London and Guy's and St. Thomas' NHS Foundation Trust (S.C.), and Royal Marsden NHS Foundation Trust (C.C.P.), London, Salford Royal NHS Foundation Trust, Salford (N.W.C.), Cardiff University School of Medicine (M.D.M.) and Velindre Cancer Centre (J.F.L.), Cardiff, Gloucestershire Royal Hospital (A.W.S.R.) and Gloucestershire Hospitals NHS Foundation Trust (J.B.), Gloucester, University of Glasgow, Glasgow (R.J.J., J.M.R.), St. James's University Hospital, Leeds (W.R.C.), University Hospital of North-Midlands, Stoke-on-Trent (F.A.), Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter (S.A.), Rosemere Cancer Centre, Royal Preston Hospital, Preston (A.J.B.), Dorset Cancer Centre, Poole Hospital, Poole (S.B.), Royal Derby Hospital, Derby (P.C.), Weston Park Hospital, Sheffield (C.F.), Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth (J.G.), Musgrove Park Hospital, Taunton (E.G.), Hull and East Yorkshire Hospitals NHS Trust, Hull (M.H.), Mount Vernon Cancer Centre, Northwood (P.J.H.), Clatterbridge Cancer Centre, Wirral (Z.I.M.), Brighton and Sussex University Hospitals NHS Trust (F.M.) and Sussex Cancer Centre, Royal Sussex County Hospital (A.R.), Brighton, NHS Highland, Inverness (N.M.), Royal Surrey County Hospital, Guildford (J.M.-K.), Northern Ireland Cancer and Queens University, Belfast (J.O.), Lancashire Teaching Hospitals NHS Trust, Preston (O.P.), Churchill Hospital, Oxford (A.P.), Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury (N.N.S.), East Kent Hospitals NHS Trust, Canterbury (C.T.), Swansea University College of Medicine, Swansea (J. Wagstaff), and Christie NHS Foundation Trust, Manchester (J. Wylie) - all in the United Kingdom; and the Department of Medical Oncology, Kantonsspital St. Gallen, St. Gallen (S.G.), and University Hospital of Lausanne, Lausanne (D.R.B.) - both in Switzerland. Two of the authors (D.M., R.M.) were unaffiliated lay members of the STAMPEDE investigators. · Pubmed 28578639
2016
  • From the *Prostate Cancer Unit, Spanish National Cancer Research Centre (CNIO); and †HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain; ‡Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research; and §Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; and ∥CNIO-IBIMA Genitourinary Cancer Unit at Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Pubmed 27749330
  • Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hôpital d'Instruction des Armées Val-de-Grâce; Stéphane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; Antoine Thiery-Vuillemin, Jean Minjoz Hospital, Besançon; Nadine Houédé, Institut de Cancérologie du Gard-Centre Hospitalier Universitaire Caremeau, Nîmes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis für Urologie; Kurt Miller, Charité-Universitätsmedizin Berlin, Berlin; Martin Bögemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nürtingen; Arnulf Stenzl, University Hospital, Tübingen, Germany; Fred Saad, Centre Hospitalier de I'Université de Montréal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia. · Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hôpital d'Instruction des Armées Val-de-Grâce; Stéphane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; Antoine Thiery-Vuillemin, Jean Minjoz Hospital, Besançon; Nadine Houédé, Institut de Cancérologie du Gard-Centre Hospitalier Universitaire Caremeau, Nîmes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis für Urologie; Kurt Miller, Charité-Universitätsmedizin Berlin, Berlin; Martin Bögemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nürtingen; Arnulf Stenzl, University Hospital, Tübingen, Germany; Fred Saad, Centre Hospitalier de I'Université de Montréal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia. · Pubmed 27400947
  • From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.). · Pubmed 27433846
  • Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Pubmed 26951312
2015
  • From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.). · Pubmed 26510020
  • Prostate Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 25920479
  • Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25800753
  • Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25624432
2014
  • Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 24390422
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 24108540
  • Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 25225437
  • Authors' Affiliations: Royal Marsden NHS Foundation Trust and The Institute of Cancer Research UK, Sutton; Institut Català d'Oncologia, L'Hospitalet, Barcelona; University of Surrey, Surrey, United Kingdom; Yale University Cancer Center, New Haven; Centre Hospitalier de l'Universite de Montreal, Montreal; A Coruña University Hospital, A Coruña, Spain; Kantonsspital St. Gallen, St. Gallen, Switzerland; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Pfizer Inc, Groton, Connecticut; and Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. · Pubmed 24536060
  • Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Sciences, Institute of Cancer Research/Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK. · Pubmed 24490608
2013
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 24188261
  • 1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK [2] Memorial Sloan-Kettering Cancer Center (MSKCC) and Weill Cornell Medical College, Center for Prostate and Urologic Cancers, New York, NY, USA. · Pubmed 24169353
  • Affiliations of authors: Department of Biostatistics and Bioinformatics, (SH, C-YL, EK), and Alliance Statistics and Data Center (SH), Duke University, Durham, NC; Departments of Medicine and Urology, University of California-San Francisco, San Francisco, CA (EJS); Division of Medical Oncology, Duke Prostate Center and the Duke Cancer Institute, Durham, NC (AJA); Departments of Medical Oncology and Urology, Yale University Cancer Center, New Haven, CT (DP); Department of Medical Oncology, San Camillo and Forlanini Hospital, Rome, Italy (CNS); Sanofi, Malvern, PA (LS); Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France (SO); Department of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, Surrey, United Kingdom (JdB); Urology Department, Tulane Cancer Center, New Orleans, LA (OS). · Pubmed 24136890
  • Susan Halabi, Andrew J. Armstrong, Ellen Kaplan, Chen-Yen Lin, and Nicole C. Solomon, Duke University, Durham, NC; Oliver Sartor, Tulane University, New Orleans, LA; Johann de Bono, Royal Marsden Hospital, Sutton, United Kingdom; and Eric J. Small, University of California at San Francisco, San Francisco, CA. · Pubmed 24101043
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23807167
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23928659
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23313031
2012
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 23098113
  • Drug Development Unit, The Institute of Cancer Research, ICR and Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, Sutton, Surrey, SM25PT, UK. · Pubmed 22373838
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 22229405
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 22198164
2011
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21943974
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 21826082
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21680542
  • Section of Medicine, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 21372223
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK. · Pubmed 21710270
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK. · Pubmed 21498309
2010
  • The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 21208851
  • The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 20628389
  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 20159823
  • Drug Development Unit, Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 19608618
  • The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Section of Medicine, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 20868208
2009
  • Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom. · Pubmed 19638457
  • The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 19223900
  • Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 19470933
2008
  • The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK. · Pubmed 18619560
  • The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 18495790
  • Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 18645193
Probable:    Miscellaneous institutions in New Orleans      
2018
  • From Tulane Medical School, New Orleans (O.S.); and the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London (J.S.B.). · Pubmed 29412780
2014
  • Department of Urology and Medicine, Tulane Medical School, Tulane, New Orleans, Louisiana, USA. · Pubmed 24994787
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 226 total) written by Johann Sebastian de Bono about Prostatic Neoplasms:

  • Metastatic Prostate Cancer. 2018
  • A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 2018
  • Metastatic Prostate Cancer. 2018
  • Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. 2017
  • Acquiring evidence for precision prostate cancer care. 2017
  • Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care? 2017
  • Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge. 2017
  • Rationale for Modernising Imaging in Advanced Prostate Cancer. 2017
  • The molecular underpinnings of prostate cancer: impacts on management and pathology practice. 2017
  • DNA Repair in Prostate Cancer: Biology and Clinical Implications. 2017
Show List of Full Article Records
Public Errors
Google Searches

Learn more about Johann Sebastian de Bono using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
University of London
Royal Marsden Hospital and Trust
Miscellaneous institutions in New Orleans
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
University of London
2018
  • Menarini Silicon Biosystems spa, Bologna, Italy. · Department of General, Visceral and Pediatric Surgery, Medical Faculty, University Hospital of the Heinrich- Heine-University Düsseldorf, Düsseldorf, Germany. · Unità Operativa di Oncologia Medica, Policlinico Sant'Orsola - Malpighi, Bologna, Italy. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Pubmed 29494651
  • Tulane University School of Medicine, New Orleans, LA · Institute of Cancer Research, London, United Kingdom · Pubmed 29694820
2017
  • Eastern Health & Monash University, Melbourne, Australia. · Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland and University of Bern, Switzerland. · Europa Uomo Prostate Patients, Clayhall Ilford, UK. · The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, UK. · Knight Cancer Institute, Oregon Health & Science University, Portland, USA. · BC Cancer Agency and University of British Columbia, Vancouver, Canada. · Department of Medical Oncology, Guy's Hospital, London, UK. · Monash University Eastern Health Clinical School, Melbourne, Australia. · Division of Haematology/Oncology, Columbia University Medical Center, New York. · Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. · Department of Cancer Medicine, Institut Paoli Calmette, Marseille, France. · Fred Hutchinson Cancer Research Center, University of Washington, Seattle. · Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA. · Clinical Oncology Unit, Queen Elizabeth Hospital Birmingham, University of Birmingham, Birmingham, UK. · Department of Clinical Therapeutics, David H. Koch Centre, Alexandra Hospital, University of Athens, Athens, Greece. · Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, USA. · Clinical Oncology Academic Unit, Royal Marsden NHS Foundation Trust, London, UK. · Clinical Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), San Francisco, USA. · Department of Surgery, Centre Hospitalier de Université de Montréal, Montreal, Canada. · Department of Medicine and Urology, Tulane Cancer Center, New Orleans. · Department of Medicine, University of California, San Francisco, USA. · Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. · Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, USA. · Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada. · Cliniques Universitaires Saint Luc, Brussels, Belgium. · Pubmed 28838209
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28419178
  • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 28233594
  • Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28000989
  • The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. · Pubmed 27753448
  • Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Department of Urology, Weill Cornell Medicine, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. · Sheffield Institute for Nucleic Acids, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain; Medical Oncology Department, CNIO-IBIMA Genitourinary Cancer Unit, Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. · Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 27590317
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. · Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, United Kingdom. · Academic Urology Unit, Royal Marsden Hospital, Sutton, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. Electronic address: · Pubmed 28606735
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · The University of Michigan, Ann Arbor, Michigan. · Peter MacCallum Cancer Centre, Melbourne, Australia. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28450425
  • OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Electronic address: · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Cancer Medicine, Gustave Roussy, University of Paris-Sud, Villejuif, France. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium. · Department of Medical Oncology, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. · Department of Medicine, University of Colorado School of Medicine, Aurora, CO. · Department of Medical Oncology, USC Norris Cancer Hospital, Keck Medical Center of USC, Los Angeles, CA. · Department of Biostatistics, Astellas Pharma Europe, BV, Leiden, Netherlands. · Department of Biostatistics, Medivation, Inc, San Francisco, CA. · Department of Clinical Development, Medivation, Inc, San Francisco, CA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. · Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA. · Pubmed 28344102
  • Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. Electronic address: · Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Trial Architecture Consulting, Washington, DC, USA. · Centre Antoine Lacassagne, Nice, France. · Florida Cancer Specialists, Fort Myers, FL, USA. · Department of Urology, Tübingen, Germany. · Institut Paoli Calmette, Department of Cancer Medicine, Marseille, France. · Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany. · University of Tübingen, Tübingen, Germany. · Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada. · Durham Regional Cancer Centre, Oshawa, ON, Canada. · Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. · OncoGenex Pharmaceuticals, Bothell, WA, USA. · Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Pubmed 28283282
  • Drug Development Department, Gustave Roussy, University of Paris Sud, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · BC Cancer Agency, Vancouver, Canada. · University Hospital 12 de Octubre, CIBER-ONC, Madrid, Spain. · Institute of Cancer Research, London, UK. · Institut Paoli-Calmettes, Marseille, France. · St. Augustinus Hospital, Antwerp, Belgium. · Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium. · Cedars-Sinai Medical Center, Los Angeles, CA, USA. · Medical Oncology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain. · Novartis Pharma S.A.S, Rueil-Malmaison, France. · Novartis Pharma AG, Basel, Switzerland. · Novartis Healthcare Pvt. Ltd., Hyderabad, India. · Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, France. · Pubmed 28282611
  • Department of Drug Development, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · Department of Medical Oncology, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA. · Comprehensive Cancer Center Yale School of Medicine, New Haven. · Sanofi Genzyme, Cambridge, USA. · Pubmed 28039155
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Cancer Medicine, Institute Gustave Roussy, Villejuif, France. · Department of Oncology, University of Paris, Paris, France. · Janssen Oncology Research & Development, Raritan, New Jersey. · Janssen Research & Development, Menlo Park, California. · Millennium Pharmaceuticals Inc., Cambridge, Massachusetts. · Department of Surgery, University of Montréal, Montréal, Québec, Canada. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Medicine, Weill Cornell Medical College, New York, New York. · Pubmed 27678453
  • Department of Cancer Medicine, Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France. · The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Medivation, Inc, San Francisco, California. · Memorial Sloan-Kettering Cancer Center, New York, New York. · Pubmed 27648814
  • Health Technology and Services Research Department, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. Electronic address: · Formal Methods and Tools Group, Faculty of Electrical Engineering, Mathematics and Computer Science, University of Twente, Enschede, The Netherlands. · Clinical Studies Department, The Institute of Cancer Research, London, UK. · Health Technology and Services Research Department, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. · Prostate Cancer Unit, The Institute of Cancer Research, London, UK. · Pubmed 29241901
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States. · Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States. · Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain. · The Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States. · Institute of Applied Physics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute for Biological Interfaces, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institut de Radioprotection et de Sûreté Nucléaire, PRP-ENV/SERIS/LECO, Cadarache, France. · Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom. · Botanical Institute II, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Daniel-Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria. · Institute of Nanotechnology, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Department of Physics, University of Illinois at Urbana-Champaign, Urbana, United States. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · ICREA, Passeig Lluís Companys, Barcelona, Spain. · Pubmed 28826504
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China. · Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. · Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of California at San Francisco, San Francisco, California. · Department of Urology, University of California at San Francisco, San Francisco, California. · Department of Medicine, University of California at San Francisco, San Francisco, California. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom. · Masonic Cancer Center and Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota, Minneapolis, Minnesota. · Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas. · Pubmed 28754673
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · University of California San Francisco, San Francisco, California. · Michigan Centre for Translational Pathology, Ann Arbor, Michigan. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28751446
  • The Royal Marsden NHS Foundation Trust, London, United Kingdom. · The Institute of Cancer Research, London, United Kingdom; Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. · The Institute of Cancer Research, London, United Kingdom. · The Institute of Cancer Research, London, United Kingdom. Electronic address: · Pubmed 28571827
  • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA. · The Institute of Cancer Research, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China. · Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA. · Pubmed 28383660
  • Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas. · Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Urology Institute of Xi'an Jiaotong University, Xi'an, Shaanxi, China. · Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom. · Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. · Freemason's Foundation Centre for Men's Health, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. · Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas. · Pubmed 28302679
  • Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. · Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA. · Department of Clinical Medicine, Rigshospitalet, Copenhagen, Denmark. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Division of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Medical Oncology, Astellas Pharma, Inc., Northbrook, IL, USA. · Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA. · Pubmed 28117385
  • Department of General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Urology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Department of Oral, Maxillo- and Plastic Facial Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Pubmed 28068321
  • University of Alabama at Birmingham, Birmingham, AL, USA. · McMaster University, Hamilton, Ontario, Canada. · Kantonsspital St Gallen, St Gallen, Switzerland. · Mayo Clinic, Rochester, MN, USA. · The Institute of Cancer Research, London, UK. · Pubmed 27670718
  • Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · The Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Epic Sciences, San Diego, CA, USA. · Department Urology, University of Michigan Medical School, Ann Arbor, MI, USA. · Comprehensive Cancer Center, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Pubmed 27539393
  • Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK. Electronic address: · Department of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Cancer Research UK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Department of Radiology, Medical Imaging Research Centre, University Hospitals Leuven, Leuven, Belgium. · Department of Radiology, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA. · Department of Radiology, German Cancer Research Centre Heidelberg (DKFZ), Heidelberg, Germany. · Department of Radiology, European Institute of Oncology, Milan, Italy. · Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. · Department of Urology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Drug Development Unit, Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK. · Pubmed 27317091
  • Institute of Cancer Research, London, United Kingdom · Johns Hopkins University, Baltimore, MD · Tulane University School of Medicine, New Orleans, LA · Pubmed 29083122
2016
  • The Institute of Cancer Research, London, England2The Royal Marsden National Health Service Foundation Trust, London, England. · Pubmed 26719908
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26585581
  • The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK. · Pubmed 27444228
  • Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 26873496
  • Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Academic Urology Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Clinical Academic Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Oncogenetics Team, Division of Cancer Genetics and Epidemiology, The Institute of Cancer Research, London, UK. · Erasmus University Medical Center, Rotterdam, Netherlands. · Departments of Pathology Urology, Comprehensive Cancer Center and Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada. · Division of Medical Oncology, Johns Hopkins Hospital, Baltimore, MA, USA. · Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 26074382
  • Department of Urology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: · Medical Oncology Division, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA. · Department of Urology, Medical University of South Carolina, Charleston, SC, USA. · Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO, USA. · Department of Surgery, University of Montreal Health Center, Montreal, Canada. · Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Urology, Asan Medical Center, Seoul, South Korea. · Department of Urology, Nippon Medical School Hospital, Tokyo, Japan. · Division of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC, USA. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Drug Development Unit, Institute of Cancer Research, Royal Marsden Hospital, London, UK. · Department of Early Clinical Development, Medivation, Inc., San Francisco, CA, USA. · Department of Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Department of Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Astellas Pharma, Inc., Northbrook, IL, USA. · Department of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 27006332
  • Department of Oncology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; Department of Internal Medicine, Stadtspital Waid, Tièchestrasse 99, 8037 Zurich, Switzerland. · Clinical Trial Unit, CTU, University Hospital of Basel, Schanzenstrasse 55, 4031 Basel, Switzerland. · Department of Oncology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland. · Erasmus MC, and ErasmusMC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands. · Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5, UK. · Department of Medicine & Urology, Tulane Cancer Center, 1430 Tulane Avenue, SL-42, New Orleans, 70112 LA, USA. · Pubmed 26829012
  • Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom; and · Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom. · Pubmed 27539840
  • Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Astex Pharmaceuticals, Cambridge, United Kingdom. · Department of Medicine, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. Department of Urology, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 27197266
  • From the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Cancer Therapeutics Division, 15 Cotswold Rd, Sutton SM2 5NG, England. · Pubmed 26807894
  • Department of Radiation Oncology, University of Michigan, Ann Arbor. · Department of Radiation Oncology, University of Michigan, Ann Arbor2Beaumont Hospital - Dearborn, Transitional Year Program, Dearborn, Michigan. · Department of Pathology, University of Michigan, Ann Arbor. · GenomeDx Biosciences Inc, Vancouver, British Columbia, Canada. · Department of Pathology and Laboratory Medicine, Weill Cornell Medical College and New York Presbyterian Hospitals, New York, New York. · Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. · Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Department of Urology, Mayo Clinic, Rochester, Minnesota. · City of Hope, Duarte, California. · Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, England. · Department of Radiation Oncology, University of Michigan, Ann Arbor13Michigan Center for Translational Pathology, University of Michigan, Ann Arbor14Comprehensive Cancer Center, University of Michigan, Ann Arbor. · Pubmed 26746117
  • Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK. · MRC Clinical Trials Unit at UCL, London, UK. Electronic address: · Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK. · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK. · MRC Clinical Trials Unit at UCL, London, UK. · Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds. · Department of Urology, University Hospital, Bern, Switzerland. · Patient rep, MRC Clinical Trials Unit at UCL, London, UK. · Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK. · Kent Oncology Centre, Maidstone Hospital, Maidstone, UK. · Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK. · Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland. · Kantonsspital Graubünden, Chur, Switzerland. · Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK. · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK. · Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK. · Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK. · Department of Oncology, Queen's Hospital, Romford, UK. · Beacon Centre, Musgrove Park Hospital, Taunton, UK. · Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK. · Department of Oncology, Royal Surrey County Hospital, Guildford, UK. · Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK. · Department of Oncology, Western General Hospital, Edinburgh, UK. · Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK. · Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK. · Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK. · Department of Oncology, Churchill Hospital, Oxford, UK. · Department of Oncology, Sussex Cancer Centre, Brighton, UK. · Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK. · Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK. · Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK. · Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK. · Department of Oncology, Southend & Basildon Hospitals, Essex, UK. · The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK. · Pubmed 26719232
  • Warwick Medical School, University of Warwick, Coventry, United Kingdom2University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, United Kingdom. · Medical Research Council Clinical Trials Unit, University College, London, United Kingdom. · Department of Urology, Christie NHS Foundation Trust, Manchester, United Kingdom. · Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Velindre Hospital, Cardiff, United Kingdom. · Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. · Royal Preston Hospital, Preston, United Kingdom. · Cantonal Hospital St Gallen, St Gallen, Switzerland. · Greater Manchester Group, Manchester, United Kingdom. · Leeds Beckett University, Leeds, United Kingdom. · Belfast City Hospital, Belfast, United Kingdom. · Singleton Hospital, Swansea, United Kingdom. · Royal Shrewsbury Hospital, Shrewsbury, United Kingdom. · Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. · CCO Liverpool Warrington Aintree, Liverpool, United Kingdom. · Pubmed 26606329
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 27330057
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY · Memorial Sloan Kettering Cancer Center, New York, NY. · Janssen Research & Development, Menlo Park, CA. · Janssen Research & Development, San Diego, CA. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26598756
2015
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26065613
  • Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 25251387
  • Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Guys and St Thomas' Hospital, London, UK. · Department of Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Department of Early Clinical Development, Medivation, San Francisco, CA, USA. · Health Economics and Outcomes Research, Astellas Pharma Europe, Leiden, Netherlands. · Department of Medical Affairs, Medivation, San Francisco, CA, USA. · Astellas Pharma Global Development, Northbrook, IL, USA. · Consulting, Quintiles, Hoofddorp, Netherlands. · Consulting, Quintiles, Barcelona, Spain; Department of Public Health, University of Barcelona, Barcelona, Spain. · Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 25888263
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · University of Montréal, Montréal, Québec, Canada. · Radboud University Medical Centre, Nijmegen, Netherlands. · San Camillo and Forlanini Hospitals, Rome, Italy. · Charité Berlin, Berlin, Germany. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia. · The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, United Kingdom. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Beerse, Belgium. · Janssen Research & Development, Raritan, NJ, USA. · Janssen Research & Development, Menlo Park, CA, USA. · Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Pubmed 25601341
  • The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The University of Texas MD Anderson Cancer Center, Houston, Texas. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada. · Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. · Ziekenhuisnetwerk Antwerpen-Middelheim Oncology Clinic, Antwerp, Belgium. · VU University Medical Center, Amsterdam, the Netherlands. · Janssen Research and Development, Spring House, Pennsylvania. · Janssen Research and Development, Menlo Park, California. · Janssen Research and Development, Los Angeles, California. · Janssen Research and Development, San Diego, California. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. · Pubmed 25593303
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK. · Department of Medical Oncology, Kantonsspital St Gallen, St Gallen, Switzerland. · Department of Clinical Oncology, Bristol Haematology and Oncology Centre, Bristol, UK. · Oncology, Sanofi Oncology, Cambridge. · Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology, Tulane University, New Orleans, USA. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK · Pubmed 25538172
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Department of Medical Cell BioPhysics, University of Twente, Enschede, the Netherlands. · Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26567358
  • Centre for Integrative Biology, University of Trento, Trento 38123, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. · The Institute of Cancer Research, London SW7 3RP, UK. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · Centre for Integrative Biology, University of Trento, Trento 38123, Italy. Institute for Computational Biomedicine, Weill Cornell Medicine, NY 10021, USA. Institute for Precision Medicine, Weill Cornell Medicine, NY 10021, USA. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Pubmed 26537258
  • Genentech Inc., South San Francisco, CA, USA. · The Royal Marsden National Health Service (NHS) Foundation Trust, Sutton, Surrey, UK. · The Institute of Cancer Research, London, UK. · Epic Sciences Inc., San Diego, CA, USA. · Core Diagnostics, Palo Alto, CA, USA. · Pubmed 26379078
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States. · Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom. · The Royal Marsden, London, United Kingdom. · Department of Urology, Weill Cornell Medical College, New York, United States. · Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States. · Centre for Integrative Biology, University of Trento, Trento, Italy. · Department of Surgery, Weill Cornell Medical College, New York, United States. · HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States. · Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States. · Department of Medicine, Weill Cornell Medical College, New York, United States. · Pubmed 26374986
  • Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA; Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA. · Cancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London SM2 5NG, UK. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA. · Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Interventional Radiology, Department of Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. · Department of Musculoskeletal Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA. · Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Radiology, University of Washington, Seattle, WA 98109, USA. · Department of Pathology, University of Washington Medical Center, Seattle, WA 98109, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Laboratory of Computational Oncology, CIBIO, Centre for Integrative Biology, University of Trento, 38123 Mattarello TN, Italy. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Division of Interventional Radiology, Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Department of Physiology & Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA. · The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: · Pubmed 26000489
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK. · Department of Medical Cell BioPhysics, MIRA Institute, University of Twente, 7522ND, Enschede, The Netherlands. · 1] Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK [2] Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK. · Pubmed 25719830
  • Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 25555314
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 25454616
  • University of Warwick, Coventry, UK. Electronic address: · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Queen Alexandra Hospital, Portsmouth, UK. · Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Hospital, Northwood, Middlesex, UK. · University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Royal Surrey County Hospital, Guildford, UK. · Velindre Hospital, Cardiff, UK. · Western General Hospital, Edinburgh, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Kantonsspital Graübunden, Chur, Switzerland. · Department of Urology, University Hospital, Bern, Switzerland. · Pubmed 25301760
  • Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: · Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Ulm University Medical Centre, Ulm, Germany. · Urologische Klinik und Poliklinik, Technische Universität München, Munich, Germany. · Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Department of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany. · Department of Urology, Muenster University Medical Centre, Muenster, Germany. · Pubmed 25108579
2014
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · University of Bern, Bern, Switzerland. · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Department of Urology, University Hospital, Bern, Switzerland. · Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Patient representative, Stockton-on-Tees, UK. · Patient representative, Northampton, UK. · University of Warwick, Warwick, UK. · Pubmed 24985962
  • From the Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 24857103
  • Prostate Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Clinical Studies, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Pubmed 24840076
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. Electronic address: · Pubmed 24418724
  • The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 24685433
  • Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · University of Western Sydney School of Medicine, Penrith, Australia. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Hematology & Oncology Clinics of Australia, Brisbane, Australia. · Sarah Cannon Research Institute, Nashville, TN, USA. · Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA. · Cross Cancer Institute, Edmonton, Alberta, Canada. · Laval University, Québec City, Québec, Canada. · University Hospital Leuven, Leuven, Belgium. · Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Raritan, NJ, USA. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. · Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Janssen Research & Development, Menlo Park, CA, USA. · CRCHUM, University of Montréal, Montréal, Québec, Canada. · Pubmed 24647231
  • Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 24411987
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Guy's and St. Thomas' NHS Foundation Trust, Great Maze Pond, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 24074764
  • The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. · Guy's and St. Thomas NHS Foundation Trust, United Kingdom. · The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: · Pubmed 24433842
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Academic Urology Unit, Sutton, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK. · Pubmed 24300975
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 24295792
2012
  • Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK. · Pubmed 21903605
2011
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 21612468
2010
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Pubmed 20888992
2008
  • Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom. · Pubmed 18829513
2017
  • Mario Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Anne-Claire Hardy-Bessard, Centre Armoricain d'Oncologie, Centre Armoricain de Radiothérapie, d'Imagerie Médicale et d'Oncologie-Hôpital Privé Des Côtes d'Armor, Plérin; Loïc Mourey, Institut Claudius Regaud, l'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Mustapha Chadjaa, Sanofi, Vitry-sur-Seine, France; Choung Soo Kim, Asan Medical Center, Seoul, South Korea; Lajos Géczi, National Institute of Oncology, Budapest, Hungary; Daniel Ford, City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham; Johann de Bono, Prostate Cancer Targeted Therapy Team, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom; Joan Carles, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Phillip Parente, Eastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, Victoria, Australia; Albert Font, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Gabriel Kacso, Iuliu Hatieganu Medical University, Amethyst Radiology Therapeutic Center, Cluj, Romania; Wenping Zhang, Sanofi, Bridgewater, NJ; and John Bernard, Sanofi, Cambridge, MA. · Pubmed 28809610
  • From the Institute of Cancer and Genomic Sciences, University of Birmingham (N.D.J.), and University Hospital Birmingham (A.Z.), Birmingham, the Institute of Cancer Research (J.S.B., D.P.D., G.A.), Medical Research Council Clinical Trials Unit at University College London (M.R. Spears, C.L.A., C.G., C.B., M.K.B.P., M.R. Sydes), King's College London and Guy's and St. Thomas' NHS Foundation Trust (S.C.), and Royal Marsden NHS Foundation Trust (C.C.P.), London, Salford Royal NHS Foundation Trust, Salford (N.W.C.), Cardiff University School of Medicine (M.D.M.) and Velindre Cancer Centre (J.F.L.), Cardiff, Gloucestershire Royal Hospital (A.W.S.R.) and Gloucestershire Hospitals NHS Foundation Trust (J.B.), Gloucester, University of Glasgow, Glasgow (R.J.J., J.M.R.), St. James's University Hospital, Leeds (W.R.C.), University Hospital of North-Midlands, Stoke-on-Trent (F.A.), Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter (S.A.), Rosemere Cancer Centre, Royal Preston Hospital, Preston (A.J.B.), Dorset Cancer Centre, Poole Hospital, Poole (S.B.), Royal Derby Hospital, Derby (P.C.), Weston Park Hospital, Sheffield (C.F.), Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth (J.G.), Musgrove Park Hospital, Taunton (E.G.), Hull and East Yorkshire Hospitals NHS Trust, Hull (M.H.), Mount Vernon Cancer Centre, Northwood (P.J.H.), Clatterbridge Cancer Centre, Wirral (Z.I.M.), Brighton and Sussex University Hospitals NHS Trust (F.M.) and Sussex Cancer Centre, Royal Sussex County Hospital (A.R.), Brighton, NHS Highland, Inverness (N.M.), Royal Surrey County Hospital, Guildford (J.M.-K.), Northern Ireland Cancer and Queens University, Belfast (J.O.), Lancashire Teaching Hospitals NHS Trust, Preston (O.P.), Churchill Hospital, Oxford (A.P.), Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury (N.N.S.), East Kent Hospitals NHS Trust, Canterbury (C.T.), Swansea University College of Medicine, Swansea (J. Wagstaff), and Christie NHS Foundation Trust, Manchester (J. Wylie) - all in the United Kingdom; and the Department of Medical Oncology, Kantonsspital St. Gallen, St. Gallen (S.G.), and University Hospital of Lausanne, Lausanne (D.R.B.) - both in Switzerland. Two of the authors (D.M., R.M.) were unaffiliated lay members of the STAMPEDE investigators. · Pubmed 28578639
2016
  • From the *Prostate Cancer Unit, Spanish National Cancer Research Centre (CNIO); and †HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain; ‡Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research; and §Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; and ∥CNIO-IBIMA Genitourinary Cancer Unit at Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Pubmed 27749330
  • From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.). · Pubmed 27433846
  • Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Pubmed 26951312
2015
  • From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.). · Pubmed 26510020
  • Prostate Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 25920479
  • Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25800753
  • Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25624432
  • Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Stephane Oudard, Université Paris Descartes, Paris, France; Robert Jones, Institute of Cancer Sciences, University of Glasgow, Glasgow; Johann De Bono, The Institute of Cancer Research, London, United Kingdom; Eleni Efstathiou, University of Athens Medical School, Athens; George Fountzilas, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Fred Saad, University of Montreal Hospital Center, Montreal, Canada; Ronald de Wit, Erasmus University Medical Center, Rotterdam, the Netherlands; Felipe Melo Cruz, ABC Foundation School of Medicine, Santo André; Flavio Carcano, Hospital de Cancer de Barretos, Barretos, Brazil; Albertas Ulys, Institut of Oncology, Vilnius University, Vilnius, Lithuania; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; David Agus, University of Southern California, Los Angeles, CA; Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Shih-Yuan Lee, Bindu Tejura, Niels Borgstein, Takeda Pharmaceuticals International; Iain J. Webb, Millennium: The Takeda Oncology Company, Cambridge, MA; Robert Dreicer, Cleveland Clinic, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain. · Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Stephane Oudard, Université Paris Descartes, Paris, France; Robert Jones, Institute of Cancer Sciences, University of Glasgow, Glasgow; Johann De Bono, The Institute of Cancer Research, London, United Kingdom; Eleni Efstathiou, University of Athens Medical School, Athens; George Fountzilas, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Fred Saad, University of Montreal Hospital Center, Montreal, Canada; Ronald de Wit, Erasmus University Medical Center, Rotterdam, the Netherlands; Felipe Melo Cruz, ABC Foundation School of Medicine, Santo André; Flavio Carcano, Hospital de Cancer de Barretos, Barretos, Brazil; Albertas Ulys, Institut of Oncology, Vilnius University, Vilnius, Lithuania; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; David Agus, University of Southern California, Los Angeles, CA; Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Shih-Yuan Lee, Bindu Tejura, Niels Borgstein, Takeda Pharmaceuticals International; Iain J. Webb, Millennium: The Takeda Oncology Company, Cambridge, MA; Robert Dreicer, Cleveland Clinic, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain. · Pubmed 25624429
  • Section of Medicine, The Institute of Cancer Research, London, UK. · Pubmed 25041380
2014
  • Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 24390422
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 24108540
  • Authors' Affiliations: Royal Marsden NHS Foundation Trust and The Institute of Cancer Research UK, Sutton; Institut Català d'Oncologia, L'Hospitalet, Barcelona; University of Surrey, Surrey, United Kingdom; Yale University Cancer Center, New Haven; Centre Hospitalier de l'Universite de Montreal, Montreal; A Coruña University Hospital, A Coruña, Spain; Kantonsspital St. Gallen, St. Gallen, Switzerland; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Pfizer Inc, Groton, Connecticut; and Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. · Pubmed 24536060
  • Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Sciences, Institute of Cancer Research/Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK. · Pubmed 24490608
2013
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 24188261
  • Institute of Cancer Research, London, United Kingdom. · Pubmed 23337755
  • Division of Cancer Therapeutics, Signal Transduction & Molecular Pharmacology and Clinical Pharmacology & Trials Team, Institute of Cancer Research, Sutton, SM25NG, United Kingdom. · Pubmed 23020876
  • 1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK [2] Memorial Sloan-Kettering Cancer Center (MSKCC) and Weill Cornell Medical College, Center for Prostate and Urologic Cancers, New York, NY, USA. · Pubmed 24169353
  • Affiliations of authors: Department of Biostatistics and Bioinformatics, (SH, C-YL, EK), and Alliance Statistics and Data Center (SH), Duke University, Durham, NC; Departments of Medicine and Urology, University of California-San Francisco, San Francisco, CA (EJS); Division of Medical Oncology, Duke Prostate Center and the Duke Cancer Institute, Durham, NC (AJA); Departments of Medical Oncology and Urology, Yale University Cancer Center, New Haven, CT (DP); Department of Medical Oncology, San Camillo and Forlanini Hospital, Rome, Italy (CNS); Sanofi, Malvern, PA (LS); Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France (SO); Department of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, Surrey, United Kingdom (JdB); Urology Department, Tulane Cancer Center, New Orleans, LA (OS). · Pubmed 24136890
  • The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 23810788
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23807167
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23928659
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23313031
2012
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 23098113
  • Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 22621691
  • Drug Development Unit, The Institute of Cancer Research, ICR and Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, Sutton, Surrey, SM25PT, UK. · Pubmed 22373838
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 22229405
  • Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom. · Pubmed 21986558
  • The Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK. · Pubmed 22170708
  • The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 22460813
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Pubmed 22411952
2011
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21943974
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 21826082
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21680542
  • Section of Medicine, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 21372223
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK. · Pubmed 21710270
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK. · Pubmed 21498309
2010
  • The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 20628389
  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 20159823
  • Drug Development Unit, Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 19608618
  • Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. · Pubmed 20177423
  • The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Section of Medicine, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 20868208
2009
  • Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom. · Pubmed 19638457
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Pubmed 19509232
  • The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 19962664
  • The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Pubmed 19339269
  • Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK. · Pubmed 19040532
2008
  • Institute of Cancer Research, Male Urological Cancer Research Centre, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. · Pubmed 18594527
  • Prostate Stem Cell Laboratory, Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 18398820
  • Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey SM2 5NG, UK. · Pubmed 18165275
Royal Marsden Hospital and Trust
2018
  • Menarini Silicon Biosystems spa, Bologna, Italy. · Department of General, Visceral and Pediatric Surgery, Medical Faculty, University Hospital of the Heinrich- Heine-University Düsseldorf, Düsseldorf, Germany. · Unità Operativa di Oncologia Medica, Policlinico Sant'Orsola - Malpighi, Bologna, Italy. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Pubmed 29494651
2017
  • Eastern Health & Monash University, Melbourne, Australia. · Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland and University of Bern, Switzerland. · Europa Uomo Prostate Patients, Clayhall Ilford, UK. · The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, London, UK. · Knight Cancer Institute, Oregon Health & Science University, Portland, USA. · BC Cancer Agency and University of British Columbia, Vancouver, Canada. · Department of Medical Oncology, Guy's Hospital, London, UK. · Monash University Eastern Health Clinical School, Melbourne, Australia. · Division of Haematology/Oncology, Columbia University Medical Center, New York. · Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. · Department of Cancer Medicine, Institut Paoli Calmette, Marseille, France. · Fred Hutchinson Cancer Research Center, University of Washington, Seattle. · Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA. · Clinical Oncology Unit, Queen Elizabeth Hospital Birmingham, University of Birmingham, Birmingham, UK. · Department of Clinical Therapeutics, David H. Koch Centre, Alexandra Hospital, University of Athens, Athens, Greece. · Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, USA. · Clinical Oncology Academic Unit, Royal Marsden NHS Foundation Trust, London, UK. · Clinical Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), San Francisco, USA. · Department of Surgery, Centre Hospitalier de Université de Montréal, Montreal, Canada. · Department of Medicine and Urology, Tulane Cancer Center, New Orleans. · Department of Medicine, University of California, San Francisco, USA. · Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. · Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, USA. · Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada. · Cliniques Universitaires Saint Luc, Brussels, Belgium. · Pubmed 28838209
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28419178
  • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 28233594
  • Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 28000989
  • The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. · Pubmed 27753448
  • Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Department of Urology, Weill Cornell Medicine, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. · Sheffield Institute for Nucleic Acids, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA. · Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain; Medical Oncology Department, CNIO-IBIMA Genitourinary Cancer Unit, Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. · Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 27590317
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. · Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, United Kingdom. · Academic Urology Unit, Royal Marsden Hospital, Sutton, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. Electronic address: · Pubmed 28606735
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · The University of Michigan, Ann Arbor, Michigan. · Peter MacCallum Cancer Centre, Melbourne, Australia. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28450425
  • OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Electronic address: · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Cancer Medicine, Gustave Roussy, University of Paris-Sud, Villejuif, France. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium. · Department of Medical Oncology, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. · Department of Medicine, University of Colorado School of Medicine, Aurora, CO. · Department of Medical Oncology, USC Norris Cancer Hospital, Keck Medical Center of USC, Los Angeles, CA. · Department of Biostatistics, Astellas Pharma Europe, BV, Leiden, Netherlands. · Department of Biostatistics, Medivation, Inc, San Francisco, CA. · Department of Clinical Development, Medivation, Inc, San Francisco, CA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR. · Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA. · Pubmed 28344102
  • Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. Electronic address: · Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Trial Architecture Consulting, Washington, DC, USA. · Centre Antoine Lacassagne, Nice, France. · Florida Cancer Specialists, Fort Myers, FL, USA. · Department of Urology, Tübingen, Germany. · Institut Paoli Calmette, Department of Cancer Medicine, Marseille, France. · Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany. · University of Tübingen, Tübingen, Germany. · Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada. · Durham Regional Cancer Centre, Oshawa, ON, Canada. · Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. · OncoGenex Pharmaceuticals, Bothell, WA, USA. · Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Pubmed 28283282
  • Department of Drug Development, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · Department of Medical Oncology, Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, France. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA. · Comprehensive Cancer Center Yale School of Medicine, New Haven. · Sanofi Genzyme, Cambridge, USA. · Pubmed 28039155
  • From the Inst of Cancer Research and Royal Marsden NHS Foundation Trust, Cancer Therapeutics Div, 15 Cotswold Rd, Sutton SM2 5NG, England. · Pubmed 27875103
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Cancer Medicine, Institute Gustave Roussy, Villejuif, France. · Department of Oncology, University of Paris, Paris, France. · Janssen Oncology Research & Development, Raritan, New Jersey. · Janssen Research & Development, Menlo Park, California. · Millennium Pharmaceuticals Inc., Cambridge, Massachusetts. · Department of Surgery, University of Montréal, Montréal, Québec, Canada. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. · Department of Medicine, Weill Cornell Medical College, New York, New York. · Pubmed 27678453
  • Department of Cancer Medicine, Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France. · The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Medivation, Inc, San Francisco, California. · Memorial Sloan-Kettering Cancer Center, New York, New York. · Pubmed 27648814
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States. · Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States. · Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain. · The Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States. · Institute of Applied Physics, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute for Biological Interfaces, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Institut de Radioprotection et de Sûreté Nucléaire, PRP-ENV/SERIS/LECO, Cadarache, France. · Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom. · Botanical Institute II, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Daniel-Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria. · Institute of Nanotechnology, Karlsruhe Institute of Technology, Karlsruhe, Germany. · Department of Physics, University of Illinois at Urbana-Champaign, Urbana, United States. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · ICREA, Passeig Lluís Companys, Barcelona, Spain. · Pubmed 28826504
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China. · Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. · Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas, Texas. · Department of Radiation Oncology, University of California at San Francisco, San Francisco, California. · Department of Urology, University of California at San Francisco, San Francisco, California. · Department of Medicine, University of California at San Francisco, San Francisco, California. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom. · Masonic Cancer Center and Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota, Minneapolis, Minnesota. · Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas. · Pubmed 28754673
  • The Institute of Cancer Research, London, United Kingdom. · The Royal Marsden NHS Foundation Trust, London, United Kingdom. · University of California San Francisco, San Francisco, California. · Michigan Centre for Translational Pathology, Ann Arbor, Michigan. · The Institute of Cancer Research, London, United Kingdom. · Pubmed 28751446
  • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA. · The Institute of Cancer Research, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China. · Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA. · Pubmed 28383660
  • Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA. · OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. · Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA. · Department of Clinical Medicine, Rigshospitalet, Copenhagen, Denmark. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Division of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Division of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Medical Oncology, Astellas Pharma, Inc., Northbrook, IL, USA. · Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA. · Pubmed 28117385
  • Department of General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Department of Urology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Department of Oral, Maxillo- and Plastic Facial Surgery, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany. · Pubmed 28068321
  • Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · The Institute of Cancer Research, London, UK. · Royal Marsden NHS Foundation Trust, London, UK. · Epic Sciences, San Diego, CA, USA. · Department Urology, University of Michigan Medical School, Ann Arbor, MI, USA. · Comprehensive Cancer Center, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Pubmed 27539393
  • Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK. Electronic address: · Department of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Cancer Research UK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Department of Radiology, Medical Imaging Research Centre, University Hospitals Leuven, Leuven, Belgium. · Department of Radiology, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA. · Department of Radiology, German Cancer Research Centre Heidelberg (DKFZ), Heidelberg, Germany. · Department of Radiology, European Institute of Oncology, Milan, Italy. · Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. · Department of Urology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Drug Development Unit, Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK. · Pubmed 27317091
2016
  • The Institute of Cancer Research, London, England2The Royal Marsden National Health Service Foundation Trust, London, England. · Pubmed 26719908
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. · The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26585581
  • The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK. · Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK. · Pubmed 27444228
  • Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Division of Clinical Studies, The Institute of Cancer Research, Downs Rd, Sutton, London, Surrey, SM2 5PT, UK. · Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Pubmed 26873496
  • Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Academic Urology Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Clinical Academic Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK; Oncogenetics Team, Division of Cancer Genetics and Epidemiology, The Institute of Cancer Research, London, UK. · Erasmus University Medical Center, Rotterdam, Netherlands. · Departments of Pathology Urology, Comprehensive Cancer Center and Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. · Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada. · Division of Medical Oncology, Johns Hopkins Hospital, Baltimore, MA, USA. · Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 26074382
  • Department of Urology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: · Medical Oncology Division, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA. · Department of Urology, Medical University of South Carolina, Charleston, SC, USA. · Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO, USA. · Department of Surgery, University of Montreal Health Center, Montreal, Canada. · Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Urology, Asan Medical Center, Seoul, South Korea. · Department of Urology, Nippon Medical School Hospital, Tokyo, Japan. · Division of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC, USA. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave-Roussy, Villejuif, France. · Drug Development Unit, Institute of Cancer Research, Royal Marsden Hospital, London, UK. · Department of Early Clinical Development, Medivation, Inc., San Francisco, CA, USA. · Department of Medical Affairs, Medivation, Inc., San Francisco, CA, USA. · Department of Biostatistics, Medivation, Inc., San Francisco, CA, USA. · Astellas Pharma, Inc., Northbrook, IL, USA. · Department of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 27006332
  • Department of Oncology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; Department of Internal Medicine, Stadtspital Waid, Tièchestrasse 99, 8037 Zurich, Switzerland. · Clinical Trial Unit, CTU, University Hospital of Basel, Schanzenstrasse 55, 4031 Basel, Switzerland. · Department of Oncology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland. · Erasmus MC, and ErasmusMC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands. · Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5, UK. · Department of Medicine & Urology, Tulane Cancer Center, 1430 Tulane Avenue, SL-42, New Orleans, 70112 LA, USA. · Pubmed 26829012
  • Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. · Astex Pharmaceuticals, Cambridge, United Kingdom. · Department of Medicine, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. Department of Urology, University of Washington School of Medicine and GRECC at VAPSHCS Seattle, Washington. · Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 27197266
  • From the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Cancer Therapeutics Division, 15 Cotswold Rd, Sutton SM2 5NG, England. · Pubmed 26807894
  • Department of Radiation Oncology, University of Michigan, Ann Arbor. · Department of Radiation Oncology, University of Michigan, Ann Arbor2Beaumont Hospital - Dearborn, Transitional Year Program, Dearborn, Michigan. · Department of Pathology, University of Michigan, Ann Arbor. · GenomeDx Biosciences Inc, Vancouver, British Columbia, Canada. · Department of Pathology and Laboratory Medicine, Weill Cornell Medical College and New York Presbyterian Hospitals, New York, New York. · Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. · Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania. · Department of Urology, Mayo Clinic, Rochester, Minnesota. · City of Hope, Duarte, California. · Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts. · Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, England. · Department of Radiation Oncology, University of Michigan, Ann Arbor13Michigan Center for Translational Pathology, University of Michigan, Ann Arbor14Comprehensive Cancer Center, University of Michigan, Ann Arbor. · Pubmed 26746117
  • Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK. · MRC Clinical Trials Unit at UCL, London, UK. Electronic address: · Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK. · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK. · MRC Clinical Trials Unit at UCL, London, UK. · Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds. · Department of Urology, University Hospital, Bern, Switzerland. · Patient rep, MRC Clinical Trials Unit at UCL, London, UK. · Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK. · Kent Oncology Centre, Maidstone Hospital, Maidstone, UK. · Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK. · Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland. · Kantonsspital Graubünden, Chur, Switzerland. · Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK. · Department of Medical Oncology, Guy's Hospital, London, UK. · Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK. · Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK. · Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK. · Department of Oncology, Queen's Hospital, Romford, UK. · Beacon Centre, Musgrove Park Hospital, Taunton, UK. · Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK. · Department of Oncology, Royal Surrey County Hospital, Guildford, UK. · Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK. · Department of Oncology, Western General Hospital, Edinburgh, UK. · Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK. · Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK. · Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK. · Department of Oncology, Churchill Hospital, Oxford, UK. · Department of Oncology, Sussex Cancer Centre, Brighton, UK. · Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK. · Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK. · Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK. · Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK. · Department of Oncology, Southend & Basildon Hospitals, Essex, UK. · The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK. · Pubmed 26719232
  • Warwick Medical School, University of Warwick, Coventry, United Kingdom2University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, United Kingdom. · Medical Research Council Clinical Trials Unit, University College, London, United Kingdom. · Department of Urology, Christie NHS Foundation Trust, Manchester, United Kingdom. · Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom. · Velindre Hospital, Cardiff, United Kingdom. · Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. · Royal Preston Hospital, Preston, United Kingdom. · Cantonal Hospital St Gallen, St Gallen, Switzerland. · Greater Manchester Group, Manchester, United Kingdom. · Leeds Beckett University, Leeds, United Kingdom. · Belfast City Hospital, Belfast, United Kingdom. · Singleton Hospital, Swansea, United Kingdom. · Royal Shrewsbury Hospital, Shrewsbury, United Kingdom. · Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. · CCO Liverpool Warrington Aintree, Liverpool, United Kingdom. · Pubmed 26606329
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 27330057
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY · Memorial Sloan Kettering Cancer Center, New York, NY. · Janssen Research & Development, Menlo Park, CA. · Janssen Research & Development, San Diego, CA. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26598756
2015
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 26065613
  • Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 25563847
  • Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. · Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: · Pubmed 25251387
  • Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK. · Department of Urology, Guys and St Thomas' Hospital, London, UK. · Department of Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Department of Early Clinical Development, Medivation, San Francisco, CA, USA. · Health Economics and Outcomes Research, Astellas Pharma Europe, Leiden, Netherlands. · Department of Medical Affairs, Medivation, San Francisco, CA, USA. · Astellas Pharma Global Development, Northbrook, IL, USA. · Consulting, Quintiles, Hoofddorp, Netherlands. · Consulting, Quintiles, Barcelona, Spain; Department of Public Health, University of Barcelona, Barcelona, Spain. · Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. · Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. · Pubmed 25888263
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · University of Montréal, Montréal, Québec, Canada. · Radboud University Medical Centre, Nijmegen, Netherlands. · San Camillo and Forlanini Hospitals, Rome, Italy. · Charité Berlin, Berlin, Germany. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia. · The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, United Kingdom. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Beerse, Belgium. · Janssen Research & Development, Raritan, NJ, USA. · Janssen Research & Development, Menlo Park, CA, USA. · Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Pubmed 25601341
  • The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom. · The University of Texas MD Anderson Cancer Center, Houston, Texas. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada. · Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. · Ziekenhuisnetwerk Antwerpen-Middelheim Oncology Clinic, Antwerp, Belgium. · VU University Medical Center, Amsterdam, the Netherlands. · Janssen Research and Development, Spring House, Pennsylvania. · Janssen Research and Development, Menlo Park, California. · Janssen Research and Development, Los Angeles, California. · Janssen Research and Development, San Diego, California. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. · Pubmed 25593303
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK. · Department of Medical Oncology, Kantonsspital St Gallen, St Gallen, Switzerland. · Department of Clinical Oncology, Bristol Haematology and Oncology Centre, Bristol, UK. · Oncology, Sanofi Oncology, Cambridge. · Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology, Tulane University, New Orleans, USA. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton (Surrey), UK · Pubmed 25538172
  • Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: · Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weil Cornell Medical College, New York, NY, USA. · Genitourinary Oncology Program, Massachusetts General Hospital, Boston, MA, USA. · Cancer Outcomes Research Program, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA. · Clinical Development, Exelixis, Inc., South San Francisco, CA, USA. · Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA. · Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. · Genitourinary Medical Oncology, Duke University Medical Center, Durham, NC, USA. · Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. · Urologic Surgery and Oncology, University of California San Francisco, San Francisco, CA, USA. · Tulane Cancer Center, Tulane University, New Orleans, LA, USA. · Pinnacle Oncology Hematology, Scottsdale, AZ, USA. · Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. · Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, UK. · Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. · Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 24631409
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Department of Medical Cell BioPhysics, University of Twente, Enschede, the Netherlands. · Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 26567358
  • Centre for Integrative Biology, University of Trento, Trento 38123, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. · The Institute of Cancer Research, London SW7 3RP, UK. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola 47014, Italy. · Centre for Integrative Biology, University of Trento, Trento 38123, Italy. Institute for Computational Biomedicine, Weill Cornell Medicine, NY 10021, USA. Institute for Precision Medicine, Weill Cornell Medicine, NY 10021, USA. · The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. · Pubmed 26537258
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States. · Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom. · The Royal Marsden, London, United Kingdom. · Department of Urology, Weill Cornell Medical College, New York, United States. · Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States. · Centre for Integrative Biology, University of Trento, Trento, Italy. · Department of Surgery, Weill Cornell Medical College, New York, United States. · HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States. · Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States. · Department of Medicine, Weill Cornell Medical College, New York, United States. · Pubmed 26374986
  • Icahn Institute for Genomics and Multiscale Biology, New York, NY, 10029, USA. · Department of Genetics and Genomic Sciences, New York, USA. · The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. · Department of Urology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. · Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. · Prostate Cancer clinical research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. · Medical Oncology Deparment, CNIO-IBIMA Genitourinary Cancer Clinical Research Unit, hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain. · Icahn Institute for Genomics and Multiscale Biology, New York, NY, 10029, USA. · Department of Genetics and Genomic Sciences, New York, USA. · The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. · The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. · Pubmed 26297150
  • Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA; Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA. · Cancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London SM2 5NG, UK. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; New York Presbyterian Hospital, New York, NY 10021, USA; Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Computational Biology Program, Public Health Sciences Division and Basic Science Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA. · Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Interventional Radiology, Department of Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA. · Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. · Department of Musculoskeletal Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA. · Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA. · Department of Radiology, University of Washington, Seattle, WA 98109, USA. · Department of Pathology, University of Washington Medical Center, Seattle, WA 98109, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Laboratory of Computational Oncology, CIBIO, Centre for Integrative Biology, University of Trento, 38123 Mattarello TN, Italy. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Division of Interventional Radiology, Department of Radiology, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Department of Physiology & Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA; Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10021, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA. · The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. · Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98109, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Meyer Cancer, Weill Medical College of Cornell University, New York, NY 10021, USA. · Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: · Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: · Pubmed 26000489
  • Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK. · Department of Medical Cell BioPhysics, MIRA Institute, University of Twente, 7522ND, Enschede, The Netherlands. · 1] Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK [2] Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK. · Pubmed 25719830
  • Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Diagnostic Radiology Department, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 25555314
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 25454616
  • University of Warwick, Coventry, UK. Electronic address: · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Queen Alexandra Hospital, Portsmouth, UK. · Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. · Mount Vernon Hospital, Northwood, Middlesex, UK. · University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · Royal Surrey County Hospital, Guildford, UK. · Velindre Hospital, Cardiff, UK. · Western General Hospital, Edinburgh, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Kantonsspital Graübunden, Chur, Switzerland. · Department of Urology, University Hospital, Bern, Switzerland. · Pubmed 25301760
  • Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: · Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, University of Copenhagen, Denmark. · Department of Urology, Ulm University Medical Centre, Ulm, Germany. · Urologische Klinik und Poliklinik, Technische Universität München, Munich, Germany. · Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom. · Department of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany. · Department of Urology, Muenster University Medical Centre, Muenster, Germany. · Pubmed 25108579
2014
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. · Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: · Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK. · Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. · University of Bern, Bern, Switzerland. · Medical Research Council Clinical Trials Unit at University College London, London, UK. · Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. · Department of Urology, University Hospital, Bern, Switzerland. · Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Patient representative, Stockton-on-Tees, UK. · Patient representative, Northampton, UK. · University of Warwick, Warwick, UK. · Pubmed 24985962
  • From the Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 24857103
  • Prostate Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Division of Clinical Studies, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. · Pubmed 24840076
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, SM2 5PT Sutton, Surrey, UK. Electronic address: · Pubmed 24418724
  • The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: · Pubmed 24685433
  • Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · MD Anderson Cancer Center, Houston, TX, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · University of Western Sydney School of Medicine, Penrith, Australia. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Hematology & Oncology Clinics of Australia, Brisbane, Australia. · Sarah Cannon Research Institute, Nashville, TN, USA. · Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA. · Cross Cancer Institute, Edmonton, Alberta, Canada. · Laval University, Québec City, Québec, Canada. · University Hospital Leuven, Leuven, Belgium. · Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA. · University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Raritan, NJ, USA. · Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. · Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Janssen Research & Development, Menlo Park, CA, USA. · CRCHUM, University of Montréal, Montréal, Québec, Canada. · Pubmed 24647231
  • Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: · Pubmed 24411987
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Guy's and St. Thomas' NHS Foundation Trust, Great Maze Pond, London, UK. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. Electronic address: · Pubmed 24074764
  • The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. · Guy's and St. Thomas NHS Foundation Trust, United Kingdom. · The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: · Pubmed 24433842
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Academic Urology Unit, Sutton, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK. · Pubmed 24300975
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 24295792
2012
  • Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK. · Pubmed 21903605
2011
  • Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 21612468
2010
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Pubmed 20888992
2008
  • Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom. · Pubmed 18829513
2017
  • Mario Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Anne-Claire Hardy-Bessard, Centre Armoricain d'Oncologie, Centre Armoricain de Radiothérapie, d'Imagerie Médicale et d'Oncologie-Hôpital Privé Des Côtes d'Armor, Plérin; Loïc Mourey, Institut Claudius Regaud, l'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Mustapha Chadjaa, Sanofi, Vitry-sur-Seine, France; Choung Soo Kim, Asan Medical Center, Seoul, South Korea; Lajos Géczi, National Institute of Oncology, Budapest, Hungary; Daniel Ford, City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham; Johann de Bono, Prostate Cancer Targeted Therapy Team, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom; Joan Carles, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Phillip Parente, Eastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, Victoria, Australia; Albert Font, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Gabriel Kacso, Iuliu Hatieganu Medical University, Amethyst Radiology Therapeutic Center, Cluj, Romania; Wenping Zhang, Sanofi, Bridgewater, NJ; and John Bernard, Sanofi, Cambridge, MA. · Pubmed 28809610
  • From the Institute of Cancer and Genomic Sciences, University of Birmingham (N.D.J.), and University Hospital Birmingham (A.Z.), Birmingham, the Institute of Cancer Research (J.S.B., D.P.D., G.A.), Medical Research Council Clinical Trials Unit at University College London (M.R. Spears, C.L.A., C.G., C.B., M.K.B.P., M.R. Sydes), King's College London and Guy's and St. Thomas' NHS Foundation Trust (S.C.), and Royal Marsden NHS Foundation Trust (C.C.P.), London, Salford Royal NHS Foundation Trust, Salford (N.W.C.), Cardiff University School of Medicine (M.D.M.) and Velindre Cancer Centre (J.F.L.), Cardiff, Gloucestershire Royal Hospital (A.W.S.R.) and Gloucestershire Hospitals NHS Foundation Trust (J.B.), Gloucester, University of Glasgow, Glasgow (R.J.J., J.M.R.), St. James's University Hospital, Leeds (W.R.C.), University Hospital of North-Midlands, Stoke-on-Trent (F.A.), Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter (S.A.), Rosemere Cancer Centre, Royal Preston Hospital, Preston (A.J.B.), Dorset Cancer Centre, Poole Hospital, Poole (S.B.), Royal Derby Hospital, Derby (P.C.), Weston Park Hospital, Sheffield (C.F.), Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth (J.G.), Musgrove Park Hospital, Taunton (E.G.), Hull and East Yorkshire Hospitals NHS Trust, Hull (M.H.), Mount Vernon Cancer Centre, Northwood (P.J.H.), Clatterbridge Cancer Centre, Wirral (Z.I.M.), Brighton and Sussex University Hospitals NHS Trust (F.M.) and Sussex Cancer Centre, Royal Sussex County Hospital (A.R.), Brighton, NHS Highland, Inverness (N.M.), Royal Surrey County Hospital, Guildford (J.M.-K.), Northern Ireland Cancer and Queens University, Belfast (J.O.), Lancashire Teaching Hospitals NHS Trust, Preston (O.P.), Churchill Hospital, Oxford (A.P.), Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury (N.N.S.), East Kent Hospitals NHS Trust, Canterbury (C.T.), Swansea University College of Medicine, Swansea (J. Wagstaff), and Christie NHS Foundation Trust, Manchester (J. Wylie) - all in the United Kingdom; and the Department of Medical Oncology, Kantonsspital St. Gallen, St. Gallen (S.G.), and University Hospital of Lausanne, Lausanne (D.R.B.) - both in Switzerland. Two of the authors (D.M., R.M.) were unaffiliated lay members of the STAMPEDE investigators. · Pubmed 28578639
2016
  • From the *Prostate Cancer Unit, Spanish National Cancer Research Centre (CNIO); and †HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain; ‡Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research; and §Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; and ∥CNIO-IBIMA Genitourinary Cancer Unit at Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain. · Pubmed 27749330
  • Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hôpital d'Instruction des Armées Val-de-Grâce; Stéphane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; Antoine Thiery-Vuillemin, Jean Minjoz Hospital, Besançon; Nadine Houédé, Institut de Cancérologie du Gard-Centre Hospitalier Universitaire Caremeau, Nîmes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis für Urologie; Kurt Miller, Charité-Universitätsmedizin Berlin, Berlin; Martin Bögemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nürtingen; Arnulf Stenzl, University Hospital, Tübingen, Germany; Fred Saad, Centre Hospitalier de I'Université de Montréal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia. · Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hôpital d'Instruction des Armées Val-de-Grâce; Stéphane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; Antoine Thiery-Vuillemin, Jean Minjoz Hospital, Besançon; Nadine Houédé, Institut de Cancérologie du Gard-Centre Hospitalier Universitaire Caremeau, Nîmes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis für Urologie; Kurt Miller, Charité-Universitätsmedizin Berlin, Berlin; Martin Bögemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nürtingen; Arnulf Stenzl, University Hospital, Tübingen, Germany; Fred Saad, Centre Hospitalier de I'Université de Montréal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia. · Pubmed 27400947
  • From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.). · Pubmed 27433846
  • Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. · Pubmed 26951312
2015
  • From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.). · Pubmed 26510020
  • Prostate Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 25920479
  • Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25800753
  • Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. · Pubmed 25624432
2014
  • Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 24390422
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 24108540
  • Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom. · Pubmed 25225437
  • Authors' Affiliations: Royal Marsden NHS Foundation Trust and The Institute of Cancer Research UK, Sutton; Institut Català d'Oncologia, L'Hospitalet, Barcelona; University of Surrey, Surrey, United Kingdom; Yale University Cancer Center, New Haven; Centre Hospitalier de l'Universite de Montreal, Montreal; A Coruña University Hospital, A Coruña, Spain; Kantonsspital St. Gallen, St. Gallen, Switzerland; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Pfizer Inc, Groton, Connecticut; and Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. · Pubmed 24536060
  • Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Sciences, Institute of Cancer Research/Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK. · Pubmed 24490608
2013
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 24188261
  • 1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK [2] Memorial Sloan-Kettering Cancer Center (MSKCC) and Weill Cornell Medical College, Center for Prostate and Urologic Cancers, New York, NY, USA. · Pubmed 24169353
  • Affiliations of authors: Department of Biostatistics and Bioinformatics, (SH, C-YL, EK), and Alliance Statistics and Data Center (SH), Duke University, Durham, NC; Departments of Medicine and Urology, University of California-San Francisco, San Francisco, CA (EJS); Division of Medical Oncology, Duke Prostate Center and the Duke Cancer Institute, Durham, NC (AJA); Departments of Medical Oncology and Urology, Yale University Cancer Center, New Haven, CT (DP); Department of Medical Oncology, San Camillo and Forlanini Hospital, Rome, Italy (CNS); Sanofi, Malvern, PA (LS); Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France (SO); Department of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, Surrey, United Kingdom (JdB); Urology Department, Tulane Cancer Center, New Orleans, LA (OS). · Pubmed 24136890
  • Susan Halabi, Andrew J. Armstrong, Ellen Kaplan, Chen-Yen Lin, and Nicole C. Solomon, Duke University, Durham, NC; Oliver Sartor, Tulane University, New Orleans, LA; Johann de Bono, Royal Marsden Hospital, Sutton, United Kingdom; and Eric J. Small, University of California at San Francisco, San Francisco, CA. · Pubmed 24101043
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23807167
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23928659
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, UK. · Pubmed 23313031
2012
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 23098113
  • Drug Development Unit, The Institute of Cancer Research, ICR and Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, Sutton, Surrey, SM25PT, UK. · Pubmed 22373838
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. · Pubmed 22229405
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 22198164
2011
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21943974
  • Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 21826082
  • Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. · Pubmed 21680542
  • Section of Medicine, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 21372223
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK. · Pubmed 21710270
  • Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK. · Pubmed 21498309
2010
  • The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 21208851
  • The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 20628389
  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 20159823
  • Drug Development Unit, Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. · Pubmed 19608618
  • The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Section of Medicine, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK. · Pubmed 20868208
2009
  • Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom. · Pubmed 19638457
  • The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 19223900
  • Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 19470933
2008
  • The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK. · Pubmed 18619560
  • The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. · Pubmed 18495790
  • Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. · Pubmed 18645193
Miscellaneous institutions in New Orleans
2018
  • From Tulane Medical School, New Orleans (O.S.); and the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London (J.S.B.). · Pubmed 29412780
2014
  • Department of Urology and Medicine, Tulane Medical School, Tulane, New Orleans, Louisiana, USA. · Pubmed 24994787
Unspecified
2017
  • Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK. Electronic address: · Department of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Cancer Research UK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK. · Department of Radiology, Medical Imaging Research Centre, University Hospitals Leuven, Leuven, Belgium. · Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Service of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. · Department of Radiology, European Institute of Oncology, Milan, Italy. · Department of Radiology, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany. · Department of Urology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. · Drug Development Unit, Institute of Cancer Research and the Royal Marsden NHS Trust, Surrey, UK. · Pubmed 28753774
  • Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. Electronic address: · University of Montréal, Montréal, Québec, Canada. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College New York, NY, USA. · Radboud University Medical Centre, Nijmegen, The Netherlands. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Janssen Research & Development, San Diego, CA, USA. · Johnson & Johnson Medical China, Shanghai, China. · Janssen Research & Development, Beerse, Belgium. · Janssen Global Services, Raritan, NJ, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Pubmed 28314611
  • The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. Electronic address: · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · Centre Hospitalier University of Montréal, Montréal, Québec, Canada. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Janssen Research & Development, Beerse, Belgium. · Janssen Research & Development, San Diego, CA, USA. · Johnson & Johnson Medical China, Shanghai, China. · Janssen Global Services, Raritan, NJ, USA. · University of Colorado Cancer Center, Aurora, CO, USA. · Pubmed 27402060
  • The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. Electronic address: · Pubmed 27751730
  • The Institute of Cancer Research, Sutton, UK. Electronic address: · Pubmed 27544577
2016
  • Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada · Janssen Research & Development, San Diego. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco. · Janssen Research & Development, Menlo Park. · Department of Solid Tumor Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston. · Comprehensive Cancer Centers of Nevada, Las Vegas. · Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA. · Groupe Uro-Genitologie, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Johnson & Johnson Medical China, Shanghai, China. · Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada. · Tom Baker Cancer Center and University of Calgary, Calgary. · Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada. · Drug Development Unit, Division of Cancer Therapeutics/Clinical Studies, The Institute for Cancer Research and Royal Marsden Hospital, Sutton, UK. · Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA. · Pubmed 26685010
  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France · University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, USA. · Saarland University, Homburg/Saar, Germany. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco. · Janssen Research & Development, San Diego. · Janssen Research & Development, Raritan. · Janssen Global Services, Raritan. · Janssen Research & Development, Los Angeles. · Janssen Research & Development, Menlo Park, USA. · Pubmed 26609008
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: · Janssen Research & Development, San Diego, CA, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · University of Montréal, Montréal, Québec, Canada. · Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Monash University and Eastern Health, Victoria, Australia. · ZNA Middelheim Oncology Clinic, Medical Oncology, Antwerp, Belgium. · Churchill Hospital, Oxford, UK. · Janssen Research & Development, Menlo Park, CA, USA. · Janssen Research & Development, Beerse, Belgium. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. · Georges Pompidou Hospital, University René Descartes, Paris, France. · Pubmed 26508309
  • Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. · DNA Damage Response Biology, Oncology IMED, AstraZeneca, Hodgkin Building, B900 Chesterford Research Park, Little Chesterford, Cambridge CB10 1XL, U.K. · Drug Development Unit, Institute of Cancer Research and Royal Marsden National Health Service Foundation Trust, London SM2 5PT, U.K. · Pubmed 27797957
  • Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK; Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. · Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; CNIO-IBIMA Genitourinary Cancer Unit, Department of Medical Oncology, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain. · Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Medical Affairs, Janssen Diagnostics, Beerse, Belgium. · Janssen Research & Development, Menlo Park, CA, USA. · Janssen Research & Development, La Jolla, CA, USA. · MIRA Research Institute for Biomedical Technology and Technical Medicine, University of Twente, Twente, The Netherlands. · Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address: · Pubmed 27289566
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Oncohematology Department, Kantonsspital St. Gallen, St. Gallen, Switzerland. · Eastern Health Medicine School, Monash University, Box Hill, VC, Australia. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address: · Pubmed 27246360
  • Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK. · Department of Medicine, University of Washington School of Medicine and VAPSHCS-GRECC, Seattle, WA, USA. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK; Medical Oncology Department, Hospital Universitario La Fe, Valencia, Spain. · Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: · Department of Medicine, University of Washington School of Medicine and VAPSHCS-GRECC, Seattle, WA, USA. Electronic address: · Pubmed 27117751
  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · BC Cancer Agency, Vancouver, BC, Canada. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. · Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. · Charité-Universitätsmedizin Berlin, Berlin, Germany. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · Janssen Research & Development, Beerse, Belgium. · Janssen Research & Development, Horsham, PA, USA. · Janssen Scientific Affairs, Horsham, PA, USA. · Janssen Research & Development, Raritan, NJ, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Global Services, Raritan, NJ, USA. · University of Washington, Seattle, WA, USA. · Pubmed 26965562
  • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: · Pubmed 26965561
  • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: · Pubmed 27240941
  • Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton. · Pubmed 27072184
2015
  • Royal Marsden Hospital, Sutton, UK. Electronic address: · Institute of Cancer Research, Sutton, UK. · Pubmed 25442054
  • Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK. · Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. · Pubmed 24837363
  • Bristol Haematology and Oncology Centre, Bristol, UK. · Clatterbridge Centre for Oncology, Wirral, UK. · Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK. · Nottingham University Hospitals NHS Trust, Nottingham, UK. · University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. · School of Cancer Sciences, University of Birmingham, Birmingham, UK. · Velindre Hospital, Cardiff, UK. · St James's University Hospital, Leeds, UK. · South Devon Healthcare NHS Foundation Trust, Torquay, UK. · Guy's and St. Thomas' NHS Foundation Trust, London, UK. · The Christie NHS Foundation Trust, Manchester, UK. · The Institute for Cancer Research and Royal Marsden Hospital, Sutton, UK. · Pubmed 25639506
  • Ipswich Hospital NHS and University Campus Suffolk, Ipswich, UK. · Institute of Cancer Research, Sutton, UK. · Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai, India. · Royal Marsden Hospital, Sutton, UK. · Royal Marsden Hospital, Sutton, UK. Electronic address: · Pubmed 25457497
  • University of Montreal Hospital Centre, Montreal, QC, Canada. Electronic address: · Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. · Carolina Urologic Research Center, Myrtle Beach, SC, USA. · Gustave Roussy, Cancer Campus Grand Paris, University of Paris Sud, Villejuif, France. · Medivation, Inc., San Francisco, CA, USA. · Astellas Global Medical Affairs, Inc., Northbrook, IL, USA. · Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Pubmed 25171902
  • Department of Oncology/Haematology, Kantonsspital St Gallen, St Gallen, Switzerland · Department of Oncology/Haematology, Kantonsspital St Gallen, St Gallen, Switzerland. · Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston Department of Genitourinary Medical Oncology, David H. Koch Centre, The University of Texas M. D. Anderson Cancer Centre, Houston, USA Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece. · Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Department of Biostatistics and Bioinformatics, Duke University, Durham. · Division of Human Biology, Fred Hutchinson Cancer Research Centre, Seattle. · Tulane Cancer Centre, Tulane University, New Orleans. · Massachusetts General Hospital Cancer Centre, Boston. · Prostate Cancer Foundation, Santa Monica, USA. · Research Centre for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. · Oregon Health & Science University Knight Cancer Institute, Portland. · Department of Medicine, Weill Cornell Medical College, New York. · Michigan Centre for Translational Pathology, Department of Pathology Department of Urology, Comprehensive Cancer Centre Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, USA. · Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. · Monash University and Eastern Health, Eastern Health Clinical School, Box Hill, Australia. · Cancer Research Centre, University of Warwick, Warwick, UK Ludwig Boltzmann Institute for Applied Cancer Research, Kaiser Franz Josef-Spital, Vienna, Austria. · Johns Hopkins Sidney Kimmel Cancer Center and The Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, USA. · The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. · Department of Nuclear Medicine, Policlinico S. Orsola, University of Bologna, Bologna, Italy. · Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada. · Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. · University of Michigan Comprehensive Cancer Center, Ann Arbor, USA. · Cancer Research Centre, University of Warwick, Warwick, UK Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, Birmingham, UK. · Department of Radiology, Centre du Cancer et Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Brussels, Belgium. · Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston Department of Genitourinary Medical Oncology, David H. Koch Centre, The University of Texas M. D. Anderson Cancer Centre, Houston, USA. · Europa Uomo Prostate Patients, Clayhall Ilford, UK. · Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. · Division of Haematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. · Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain. · Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood. · Prostate Cancer Targeted Therapy Group, Academic Urology Unit and Department of Diagnostic Radiology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. · Institute for Precision Medicine, Meyer Cancer Center, Department of Pathology and Urology, Weill Cornell Medical College and NewYork Presbyterian, New York, USA. · Department of Urology, Radboud University, Medical Centre, Nijmegen, The Netherlands. · Department of Medicine, Weill Cornell Medical College, New York Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York. · Department of Oncology, Assaf Harofeh Medical Centre, Tel-Aviv University, Sackler School of Medicine, Zerifin, Israel. · Department of Urology, Carolina Urologic Research Centre, Myrtle Beach. · Helen Diller Family Comprehensive Cancer Centre, UCSF, San Francisco, USA. · Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Urology, Toho University Sakura Medical Center, Chiba, Japan. · Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, USA. · Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Canada. · Service D'Urologie, Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. · Pubmed 26041764
  • University of Montréal, Montréal, Québec, Canada. Electronic address: · Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. · University Hospital Leuven, Leuven, Belgium. · Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. · Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK. · MD Anderson Cancer Center, Houston, TX, USA. · University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Hematology and Oncology Clinics of Australia, Brisbane, Australia. · Sarah Cannon Research Institute, Nashville, TN, USA. · Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA. · Cross Cancer Institute, Edmonton, Alberta, Canada. · Laval University, Québec City, Québec, Canada. · Janssen Research & Development, Los Angeles, CA, USA. · Janssen Research & Development, Beerse, Belgium. · Janssen Research & Development, Raritan, NJ, USA. · Janssen Research & Development, San Diego, CA, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Janssen Research & Development, Menlo Park, CA, USA. · Pubmed 25985882
  • Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland. Electronic address: · Tulane University, Department of Medicine and Urology, New Orleans, LA. · Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland. · Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland. · Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, ICR, Sutton, UK. · Sanofi-Aventis, Bridgewater, NJ. · Pubmed 25733056
  • Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: · Janssen Research and Development, Los Angeles, CA, USA. · Janssen Research and Development, Menlo Park, CA, USA. · Janssen Research and Development, Raritan, NJ, USA. · Dana-Farber Cancer Institute, Boston, MA, USA. · Institut Gustave Roussy, Villejuif, France. · The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. · Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, UK. · Pubmed 25018037
2014
  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: · Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. · Charité Berlin, Berlin, Germany. · Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. · San Camillo and Forlanini Hospitals, Rome, Italy. · Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. · Medivation, San Francisco, CA, USA. · Royal Marsden Hospital and the Institute of Cancer Research, Sutton, UK. · Pubmed 25104109
  • Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. · University of Colorado Cancer Center, Aurora, CO, USA. · Janssen Research & Development, Los Angeles, CA, USA. · Radboud University Medical Centre, Nijmegen, The Netherlands. · Institut Gustave Roussy, University of Paris Sud, Villejuif, France. · Urologikum Hamburg, Hamburg, Germany. · Janssen Research & Development, Raritan, NJ, USA. · The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. · Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College, New York, NY, USA. · Pubmed 24080993
  • Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK. · 1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK [2] Kantonsspital St. Gallen, Department of Oncology and Haematology, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland. · Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, Surrey, UK. · Kantonsspital St. Gallen, Department of Oncology and Haematology, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland. · Pubmed 25314055
2014
  • Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation,UK. Electronic address: · Pubmed 23958310
  • The authors' affiliations are listed in the Appendix. · Pubmed 24881730
  • Departments of Medical Oncology and Haematology. · Pubmed 24458472
2013
  • Institute of Cancer Research and Royal Marsden Hospit